Venezuelan Equine Encephalitis Virus: Veterinary Reference

Overview and Taxonomy of Venezuelan Equine Encephalitis Virus: Veterinary Reference

Introduction and Historical Context

Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne, positive-sense, single-stranded RNA virus belonging to the genus Alphavirus within the family Togaviridae [16, 25]. This pathogen represents one of the most significant arthropod-borne viral threats to equine and human health in the Americas, classified as a Category B select agent by the United States Centers for Disease Control and Prevention (CDC) due to its potential for aerosolization and high infectivity [21, 26, 30]. The virus is the etiological agent of Venezuelan equine encephalitis (VEE), a disease characterized by a biphasic febrile illness that can progress to severe, often fatal, encephalitis in both horses and humans [20, 25]. The World Organisation for Animal Health (WOAH) recognizes VEE as a notifiable disease of critical economic and veterinary importance, given its capacity to cause devastating epizootics with equine mortality rates reaching up to 80% [22, 27].

The history of VEEV is punctuated by periodic, explosive outbreaks across tropical and subtropical regions of the Americas. Major epizootics, often involving tens of thousands of equine deaths and thousands of human cases, have been documented in Venezuela, Colombia, Ecuador, Peru, and Central America [20, 35]. The virus was first isolated in 1938 from the brain of a horse in Venezuela, and subsequent characterization revealed a complex of antigenically related but genetically distinct subtypes [3, 20]. The biological and epidemiological dichotomy between enzootic (endemic) and epizootic (epidemic) strains is a defining feature of VEEV ecology and pathogenesis, a distinction that is paramount for veterinary surveillance and control strategies [3, 9].

Taxonomic Classification and Genetic Diversity

The taxonomy of VEEV is intricate, reflecting its long evolutionary history and adaptation to diverse ecological niches. The virus is classified within the VEEV complex, which is subdivided into six distinct subtypes (I through VI) based on antigenic and genetic criteria [3, 9]. Subtype I is the most heterogeneous and clinically relevant, further divided into multiple serotypes or varieties (IAB, IC, ID, IE, IF). Critically, the epizootic (epidemic) strains that cause massive equine mortality and spillover into human populations are exclusively found within subtypes IAB and IC [3, 35]. In contrast, the enzootic (endemic) strains, which circulate continuously in sylvatic cycles without causing large-scale outbreaks, include subtypes ID, IE, IF, and subtypes II through VI [9, 20].

Subtype II is known as Everglades virus (EVEV), which is endemic to Florida, USA, and is maintained in a cycle between muroid rodents (primarily the hispid cotton rat Sigmodon hispidus and the cotton mouse Peromyscus gossypinus) and the mosquito vector Culex (Melanoconion) cecedei [9]. Subtype III includes Mucambo virus (MUCV; IIIA) and other varieties found in the Amazon basin [17]. Subtype IV is Pixuna virus, subtype V is Cabassou virus, and subtype VI includes Rio Negro virus [20]. This genetic diversity has profound implications for vaccine development, diagnostic accuracy, and understanding of pathogenic potential. Phylogenetic analyses of the VEEV subtype I complex have demonstrated that the IE subtype diverged earlier than other subtypes, and isolates from Costa Rica, for example, have ancestors tracing back to Nicaragua (1963) and Guatemala (1907), highlighting the long-term circulation and geographic spread of these lineages [3].

Molecular Architecture and Structural Biology

The VEEV virion is an enveloped, icosahedral particle approximately 70 nm in diameter [14, 39]. The viral genome is approximately 11.4 kb in length and encodes four nonstructural proteins (nsP1, nsP2, nsP3, and nsP4) and five structural proteins (capsid [C], E3, E2, 6K, and E1) [25, 38]. The structural proteins are arranged on the virion surface as 80 trimeric spikes, each composed of three E2-E1 heterodimers, which are critical for receptor attachment and membrane fusion [14].

The entry receptor for VEEV has been identified as the low-density lipoprotein receptor class A domain-containing 3 (LDLRAD3), a highly conserved member of the scavenger receptor superfamily [5, 14, 18]. This receptor is expressed on neurons and other target cells, and its engagement by the virus is a critical determinant of neurotropism and pathogenesis [5]. Cryo-electron microscopy (cryo-EM) reconstructions have revealed that domain 1 of LDLRAD3 binds into a cleft created by two adjacent E2-E1 heterodimers within a single trimeric spike, engaging domains A and B of E2 and the fusion loop in E1 [14]. This interaction is structurally analogous to how arthritogenic alphaviruses bind the MXRA8 receptor, albeit with a much smaller interface [14]. The requirement for LDLRAD3 is absolute for efficient peripheral infection and neuroinvasion; Ldlrad3-deficient mice survive both intranasal and intracranial VEEV inoculation, demonstrating a profound block in pathogenesis [5].

The nonstructural proteins orchestrate viral RNA replication and transcription. nsP1 possesses both methyltransferase and guanylyltransferase activities, essential for capping the viral RNA [22, 34]. nsP2 is a multifunctional protein harboring a cysteine protease domain (nsP2pro) responsible for processing the nonstructural polyprotein, as well as helicase and RNA triphosphatase activities [6, 10, 46]. The nsP2 protease is a validated drug target, and its structure has been solved in both active and self-inhibited conformations, revealing a unique N-terminal autoinhibitory mechanism where the N-terminal residues bind to the active site [10]. nsP3 contains a hypervariable domain (HVD) that is intrinsically disordered but critical for recruiting host factors, including members of the FXR family of proteins, CD2AP, and SH3KBP1, which are essential for the assembly of functional replication complexes [31, 33]. nsP4 is the RNA-dependent RNA polymerase (RdRp), the catalytic core of the replicase complex [40].

Enzootic and Epizootic Transmission Cycles

The ecological maintenance of VEEV is characterized by two distinct transmission cycles: the enzootic (silent) cycle and the epizootic (outbreak) cycle [20, 25]. The enzootic cycle involves continuous circulation of subtypes ID, IE, and II-VI between sylvatic rodent reservoirs, primarily of the subfamily Sigmodontinae, and mosquito vectors of the Culex (Melanoconion) subgenus, particularly the Spissipes section [9, 15, 20]. These cycles occur in tropical forests, mangroves, and wetlands, where the virus persists without causing noticeable disease in the rodent hosts, which develop high-titer viremia sufficient to infect feeding mosquitoes [9, 20]. Bats have also been implicated as potential amplifying hosts; molecular and immunohistochemical evidence has confirmed natural VEEV infection in frugivorous bats such as Artibeus planirostris and Sturnira lilium in Colombia, suggesting a broader host range than previously appreciated [13, 45].

The epizootic cycle is a dramatic departure from this silent maintenance. Epizootic strains (IAB and IC) arise from enzootic precursors, likely through a series of adaptive mutations that enhance the virus's ability to replicate to high titers in equines and to be transmitted by a broader range of mosquito vectors, particularly Aedes taeniorhynchus and other floodwater mosquitoes [9, 20]. The transition from enzootic to epizootic phenotype is a rare but catastrophic event. Once established, the epizootic cycle involves rapid amplification in horses, which develop viremia levels exceeding 10^8 plaque-forming units (PFU) per milliliter of blood, sufficient to infect large numbers of mosquitoes [20, 35]. Infected mosquitoes then serve as bridge vectors, transmitting the virus to humans and other incidental hosts. This cycle can result in thousands of equine deaths and hundreds of thousands of human cases within weeks [20, 35].

Pathogenesis and Neuroinvasion

VEEV pathogenesis is a complex interplay of viral replication, host immune response, and neuroinflammation. Following inoculation by an infected mosquito or aerosol exposure, the virus replicates initially in dendritic cells and macrophages at the site of entry, then disseminates to regional lymph nodes and the spleen, causing a high-titer viremia [25, 44]. The virus must then cross the blood-brain barrier (BBB) to cause encephalitis. Multiple mechanisms contribute to neuroinvasion, including direct infection of endothelial cells, transport within infected leukocytes (the "Trojan horse" mechanism), and, critically, entry via the olfactory neuroepithelium [2, 11, 32].

The olfactory route is particularly efficient for aerosolized VEEV, which is a major concern for biodefense [2, 11]. Immature olfactory sensory neurons (OSNs) express high levels of the LDLRAD3 receptor and are the initial targets of infection in the nasal cavity [2, 11]. Despite the nasal cavity's robust antiviral defenses, VEEV suppresses type I interferon (IFN) signaling, delaying the expression of interferon-stimulated genes (ISGs) for up to 48 hours, allowing the virus to invade the olfactory bulb and subsequently spread throughout the brain [2, 11]. Once within the central nervous system (CNS), VEEV infects neurons, microglia, and astrocytes, triggering a massive pro-inflammatory response characterized by the upregulation of cytokines (TNF-α, IL-6), chemokines (CCL-2, CCL-5, CXCL-10), and matrix metalloproteinases (MMP-2, MMP-9) [7, 19, 23, 44]. This neuroinflammation is a double-edged sword; while it is essential for controlling viral replication, it also contributes to BBB disruption, neuronal apoptosis, and the clinical manifestations of encephalitis [19, 23, 32].

Toll-like receptor 4 (TLR4) has been identified as a critical mediator of BBB permeability and disease severity during VEEV infection. In a murine model, TLR4-defective mice (C3H/HeJ) survived VEEV TC-83 infection, whereas wild-type mice succumbed, despite equivalent viral titers in the brain [19]. This protection was associated with reduced BBB permeability and lower levels of MMP-9, ICAM-1, CCL-2, and IFN-γ in the brain [19]. These findings highlight the potential of targeting host inflammatory pathways, rather than the virus directly, as a therapeutic strategy.

Host-Virus Interactions and Antiviral Targets

The VEEV capsid protein is a multifunctional virulence factor that extends beyond its structural role. It possesses autoprotease activity, cleaving itself from the nascent structural polyprotein, and it also shuttles to the nucleus, where it inhibits host transcription and disrupts nucleocytoplasmic trafficking [38, 42]. The capsid protein interacts with the host importin α/β1 heterodimer to gain entry into the nucleus, and this interaction is a validated target for antiviral drug development [36, 43]. High-throughput screening has identified small molecules, such as compound G281-1564, that inhibit the importin α/β1: capsid interaction, reduce capsid nuclear accumulation, and suppress VEEV replication at low micromolar concentrations [36, 43].

The host ubiquitin-proteasome system (UPS) plays a dual role in VEEV infection. The E3 ubiquitin ligase TRIM32 has been identified as a novel intrinsic restriction factor that inhibits VEEV infection by interfering with genome translation after membrane fusion, in a manner independent of the TRIM32-STING-IFN axis [4]. Conversely, VEEV hijacks other components of the UPS to its advantage. The interaction between the E1 glycoprotein and protein disulfide isomerase family A member 6 (PDIA6) is critical for proper disulfide bond formation and production of infectious virions, and pharmacological inhibition of PDIs with LOC14 or nitazoxanide effectively reduces VEEV production [8].

The nonstructural protein nsP3 is a hub for host factor recruitment. Its hypervariable domain (HVD) binds to the FXR family of proteins, CD2AP, and SH3KBP1, which are essential for efficient viral RNA replication [33]. The phosphorylation status of nsP3, mediated by host kinases such as IKKβ, is a critical regulatory switch; alanine substitution of key phosphorylation sites (e.g., S204/5) reduces VEEV replication by over 100,000-fold due to a severe block in negative-strand RNA synthesis [28]. Similarly, the capsid protein is phosphorylated by protein kinase C delta (PKCδ), and this phosphorylation modulates viral RNA binding and assembly, with phospho-deficient mutants showing altered particle infectivity and attenuation in mice [29]. Protein phosphatase 1α (PP1α) counteracts this phosphorylation, and inhibition of the PP1α-capsid interaction with the small molecule 1E7-03 reduces VEEV replication by more than 2 logs [41].

Veterinary and Public Health Significance

From a veterinary perspective, VEEV is a devastating pathogen of equids. The disease in horses is characterized by a sudden onset of fever, depression, anorexia, and neurological signs including ataxia, hyperexcitability, circling, paralysis, and seizures [27, 37]. Mortality rates in naive equine populations during epizootics can approach 50-80% [22, 27]. The economic impact is severe, encompassing direct losses from mortality, costs of vaccination and vector control, trade restrictions, and the public health burden of human cases. The virus is a zoonotic threat; human infections typically present as an acute febrile illness with headache, myalgia, and malaise, but up to 14% of cases, particularly in children, progress to encephalitis with long-term neurological sequelae or death [1, 20, 25].

The diagnosis of VEEV in veterinary settings relies on a combination of clinical signs, serology (IgM ELISA, plaque reduction neutralization test [PRNT]), and molecular detection (real-time RT-PCR) [24, 37]. Given the overlapping clinical presentation with other arboviral encephalitides (e.g., Eastern equine encephalitis virus [EEEV], West Nile virus [WNV]), laboratory confirmation is essential [1, 27]. The development of robust, field-deployable diagnostic tools, such as magnetic Nanotrap particles that preserve viral RNA and capsid protein in blood samples at elevated temperatures, is critical for surveillance in resource-limited settings [12].

Conclusion of Section

The overview and taxonomy of Venezuelan equine encephalitis virus reveal a pathogen of remarkable complexity, characterized by a dynamic interplay between enzootic maintenance and epizootic emergence, a sophisticated molecular machinery for host cell invasion and replication, and a potent capacity to subvert host immune defenses. The genetic diversity within the VEEV complex, the identification of LDLRAD3 as the entry receptor, and the detailed understanding of host-virus interactions at the molecular level provide a foundation for the rational design of vaccines and therapeutics. The continued circulation of enzootic strains in sylvatic cycles, the potential for epizootic mutations to arise in subtypes like Everglades virus [9], and the expanding geographic range of vectors due to climate change underscore the persistent and evolving threat of VEEV to both animal and human health across the Americas.

Molecular Pathogenesis of Venezuelan Equine Encephalitis Virus: Host Interactions and Replication Factors

The molecular pathogenesis of Venezuelan equine encephalitis virus (VEEV) is a complex, multi-stage process governed by intricate interactions between viral gene products and host cellular machinery. As a member of the Togaviridae family (genus Alphavirus), VEEV possesses a single-stranded, positive-sense RNA genome of approximately 11.4 kb that encodes four nonstructural proteins (nsP1–nsP4) and five structural proteins (capsid, E3, E2, 6K, and E1) [3, 25]. The virus is classified into six subtypes (I–VI), with epizootic subtypes IAB and IC responsible for major outbreaks in equids and humans, while enzootic subtypes (ID–IF, II–VI) circulate in sylvatic cycles [3, 9, 20]. The World Organisation for Animal Health (WOAH) and the U.S. Centers for Disease Control and Prevention (CDC) recognize VEEV as a significant zoonotic pathogen and a category B select agent due to its aerosol infectivity and potential for weaponization [25, 35]. Understanding the molecular underpinnings of VEEV replication and host interaction is critical for developing targeted therapeutics and vaccines.

Viral Entry and Receptor Engagement

The initial step in VEEV infection is the attachment and entry into susceptible host cells, a process mediated by the viral glycoproteins E2 and E1. The primary entry receptor for VEEV is the low-density lipoprotein receptor class A domain-containing 3 (LDLRAD3), a highly conserved member of the scavenger receptor superfamily [18]. Using a genome-wide CRISPR–Cas9 screen, Ma et al. identified LDLRAD3 as a critical host factor for VEEV infection, demonstrating that gene editing of Ldlrad3 in mice or LDLRAD3 in human neuronal cells markedly reduces viral infection [18]. Domain 1 of LDLRAD3 (LDLRAD3(D1)) is necessary and sufficient to support infection, binding directly to VEEV particles and enhancing virus attachment and internalization [14, 18]. Cryo-electron microscopy reconstructions of VEEV virus-like particles in complex with LDLRAD3 ectodomains revealed that domain 1 of the receptor wedges into a cleft created by two adjacent E2–E1 heterodimers within a single trimeric spike, engaging domains A and B of E2 and the fusion loop in E1 [14]. This interaction is structurally analogous to how arthritogenic alphaviruses bind the MXRA8 receptor, albeit with a much smaller interface [14]. The critical role of LDLRAD3 in pathogenesis was confirmed in vivo: Ldlrad3-deficient mice survive both intranasal and intracranial VEEV inoculation, showing reduced infection of neurons across multiple brain regions [5]. This receptor is also differentially expressed on olfactory sensory neurons (OSNs), where immature OSNs express higher levels of LDLRAD3 than mature OSNs, making them the initial cellular targets following intranasal exposure [2, 11]. The development of a soluble LDLRAD3(D1)–Fc decoy receptor has shown remarkable efficacy in abolishing disease caused by several VEEV subtypes, including highly virulent strains, highlighting the therapeutic potential of receptor-targeted interventions [18].

Beyond LDLRAD3, other host factors modulate the entry process. Tetraspanins (Tspans), particularly Tspan10 and Tspan15 (members of the TspanC8 subfamily), have been identified as replication factors for VEEV in astrocytoma cells [48]. Silencing of Tspan10, Tspan15, or their interactor ADAM10 (a disintegrin and metalloproteinase 10) does not affect VEEV entry but diminishes viral genome replication, suggesting these proteins function at a post-entry step [48]. Interestingly, Tspan14, another TspanC8 family member, acts as a restriction factor for VEEV entry, as its silencing enhances infection with lentiviral pseudoparticles bearing VEEV envelope proteins [48]. The ADAM10 substrate neuronal (N)-cadherin also plays a role, as its silencing reduces VEEV infectivity, indicating that ADAM10-mediated cleavage of cell adhesion molecules may facilitate viral spread [48]. Additionally, the host ubiquitin-proteasome system (UPS) contributes to entry restriction. The E3 ubiquitin ligase TRIM32 acts as an intrinsic restriction factor against VEEV and other alphaviruses by interfering with genome translation after membrane fusion but prior to replication of the incoming viral genome [4]. TRIM32’s antiviral activity is dependent on its monoubiquitination, and pathogenic mutants of TRIM32 (R394H and D487N) associated with limb-girdle muscular dystrophy exhibit a loss of antiviral function [4]. The human cathelicidin peptide LL-37 also inhibits VEEV entry by aggregating viral particles, thereby preventing attachment and internalization [26].

Replication Complex Assembly and Nonstructural Protein Functions

Following entry and uncoating, the viral genomic RNA is translated to produce the nonstructural polyprotein, which is processed by the nsP2 cysteine protease into individual nsPs that form the viral replication complex (RC) [25, 46]. The nsP2 protease (nsP2pro) is a papain-like cysteine protease with an alternative active site motif (⁴⁷⁵NVCWAK⁴⁸⁰) and is essential for polyprotein processing and viral replication [6, 46]. High-resolution crystallographic studies have revealed that nsP2pro can adopt a self-inhibited conformation where its N-terminal residues bind to the active site, mimicking substrate binding [10]. This autoinhibition may represent a regulatory mechanism to control protease activity during the viral life cycle [10]. The protease cleaves not only the viral polyprotein but also host proteins to antagonize innate immunity. Notably, VEEV nsP2 cleaves human TRIM14, a component of the mitochondrial antiviral-signaling protein (MAVS) signalosome, thereby suppressing interferon (IFN) induction [52]. This cleavage is mediated by short stretches of homologous host-pathogen protein sequences (SSHHPS) embedded within the viral nonstructural polyprotein, representing a sophisticated mechanism of IFN antagonism [52].

The nsP1 protein possesses both methyltransferase and guanylyltransferase activities required for capping the viral genomic and subgenomic RNAs [22]. The capping reaction proceeds through the methylation of GTP to form m⁷GTP, followed by the formation of a covalent m⁷GMP-nsP1 intermediate, and finally transfer of m⁷GMP to the 5′-diphosphate end of viral RNA [22]. The efficiency of this capping process is influenced by RNA length and secondary structure, with a short, conserved stem-loop downstream of the cap serving as an essential regulatory element [22]. High-throughput screening of approved drugs against nsP1 has identified several compounds that inhibit its guanylylation activity, validating nsP1 as a druggable target [34].

The nsP3 protein is a multifunctional component of the RC, containing a hypervariable domain (HVD) that is intrinsically disordered yet critical for host factor recruitment [31, 33]. The VEEV nsP3 HVD interacts with members of the FXR family of cellular proteins (Fragile X syndrome-related proteins) through its C-terminal repeating peptide motif, and also binds the SH3 domain-containing proteins CD2AP and SH3KBP1 [33]. These interactions are essential for efficient viral replication, and VEEV can switch between FXR-dependent and G3BP-dependent replication modes, reflecting its evolutionary adaptability [33]. The HVD also undergoes phosphorylation mediated by IKKβ kinase activity, with phosphorylation at specific sites (204/5, 142, and 134/5) being essential for negative-strand RNA synthesis [28]. Alanine substitution at these sites reduces viral replication by 30- to 100,000-fold, and phosphomimetic mutations can rescue replication, underscoring the regulatory importance of nsP3 phosphorylation [28]. Mass spectrometry analysis of the VEEV nsP3 interactome has identified additional host partners, including TFAP2A and eIF2S2, with eIF2S2 supporting efficient genomic RNA synthesis [21].

The nsP4 protein functions as the RNA-dependent RNA polymerase (RdRp), and its fidelity influences viral pathogenesis and vaccine stability [40]. Low-fidelity mutations in the RdRp can increase immunogenicity but also lead to genetic instability, as seen with the TC-83 vaccine strain [40]. The benzamidine compound ML336 potently inhibits VEEV RNA synthesis by targeting the viral replicase complex, with an IC₅₀ of 1.1 nM for RNA synthesis inhibition, and resistance mutations map to nsP2 and nsP4 [54]. The quinolinone class of antivirals also targets nsP2, with resistance mutations identified at residue Y102 in the helicase stalk domain [51].

Structural Protein Functions and Host Shutoff

The VEEV capsid protein is a multifunctional virulence factor that extends beyond its structural role in nucleocapsid assembly [38]. Capsid possesses an N-terminal nuclear localization signal (NLS) and a nuclear export signal (NES), enabling it to shuttle between the cytoplasm and nucleus [38, 42]. Once in the nucleus, capsid inhibits host transcription by interacting with the CRM1 and importin α/β1 nuclear transport proteins, leading to a global shutdown of host gene expression [36, 38, 43]. This transcriptional shutoff contributes to the suppression of antiviral responses and is a key determinant of VEEV pathogenesis [38]. Capsid also induces cell cycle arrest at the G0/G1 phase in a manner dependent on its NLS and importin α binding, with downregulation of cyclins D1, A2, and E2 and loss of Rb phosphorylation [42].

Phosphorylation of capsid by protein kinase C delta (PKCδ) regulates its RNA-binding activity and viral assembly [29]. Phosphorylation at four residues reduces capsid’s affinity for viral RNA, promoting efficient assembly and release of infectious particles [29]. A mutant virus with alanine substitutions at these phosphorylation sites (VEEV CPD) exhibits a lower genomic copy-to-PFU ratio, indicating more efficient assembly, but is attenuated in mice [29]. Conversely, protein phosphatase 1α (PP1α) dephosphorylates capsid, and inhibition of PP1α with the small molecule 1E7-03 reduces viral replication by more than 2 logs, demonstrating that the phosphorylation state of capsid is a critical regulator of the viral life cycle [41]. The capsid–importin α/β1 interaction has been successfully targeted using in silico structure-based drug design, yielding compounds that inhibit capsid nuclear import and reduce VEEV replication at low micromolar concentrations [43]. High-throughput screening has further identified inhibitors of this interaction, such as compound G281-1564, which shows potent antiviral activity with minimal toxicity [36].

The E1 glycoprotein mediates membrane fusion and interacts with host chaperones, including protein disulfide isomerase family A member 6 (PDIA6) [8]. Inhibition of PDIs with LOC14 or nitazoxanide reduces VEEV production by impacting both early and late replication events, including disulfide bond formation in E1 [8]. The E1 fusion loop also contains a cryptic epitope recognized by the cross-reactive monoclonal antibody 1A4B-6, which inhibits virus entry at a pre-attachment step and protects mice from lethal VEEV challenge [50].

Host Antiviral Responses and Viral Countermeasures

VEEV infection elicits a robust type I interferon (IFN) response characterized by the induction of interferon-stimulated genes (ISGs) such as IFIT1-3, OASL, RSAD2, and MX1 [47]. Transcriptomic profiling of VEEV-infected human endothelial cells reveals a canonical ISG signature alongside cytokine and chemokine signaling (IL6, CXCL10, CXCL11), consistent with a strong proinflammatory and antiviral state [47]. However, VEEV has evolved multiple mechanisms to evade this response. The nsP2 protease-mediated cleavage of TRIM14 disrupts MAVS signaling, thereby dampening IFN induction [52]. Additionally, VEEV infection delays IFN responses in the olfactory neuroepithelium and olfactory bulb for up to 48 hours following intranasal exposure, creating a therapeutic window for intervention [2, 11]. Intranasal administration of recombinant IFNα at the time of or early after infection triggers early ISG expression, suppresses viral replication in the olfactory neuroepithelium, and inhibits neuroinvasion, extending survival in murine models [2, 11].

The NRF2 transcription factor pathway represents an alternative host defense mechanism. Treatment with the NRF2 activator omaveloxolone (OMA) redirects the host transcriptional response from an interferon-centric, inflammatory program toward an NRF2-driven cytoprotective program, inducing antioxidant genes (HMOX1, NQO1, GCLM, TXNRD1, SLC7A11) while preserving core antiviral mechanisms [47]. This approach reduces inflammation and preserves blood-brain barrier (BBB) integrity in organ-on-a-chip models [49]. Toll-like receptor 4 (TLR4) also plays a critical role in VEEV pathogenesis by mediating BBB permeability. TLR4-defective mice (C3H/HeJ) survive intranasal VEEV infection and exhibit reduced BBB permeability, lower levels of matrix metalloproteinases (MMP-9, MMP-2), and decreased expression of ICAM-1, CCL2, and IFN-γ in the brain, despite having similar viral titers to wild-type mice [19].

Cellular Stress Responses and Apoptosis

VEEV infection induces profound cellular stress, including the unfolded protein response (UPR) and mitochondrial dysfunction. The PERK (PKR-like endoplasmic reticulum kinase) arm of the UPR is activated, leading to upregulation of ATF4 and CHOP (DDIT3) [56]. This pathway drives expression of the transcription factor early growth response 1 (EGR1), which promotes apoptosis [53, 56]. EGR1 induction is dependent on both ERK1/2 and PERK signaling, and knockdown of EGR1 significantly reduces VEEV-induced apoptosis and impacts viral replication [53]. EGR1⁻/⁻ mouse embryonic fibroblasts show lower susceptibility to VEEV-induced cell death, confirming its proapoptotic role [56].

Mitochondrial dynamics are dramatically altered during VEEV infection. Infected astrocytoma cells exhibit a robust drop in mitochondrial activity, increased accumulation of reactive oxygen species (ROS), and prominent perinuclear clustering of mitochondria [55]. The mitophagy machinery, including PINK1 and Parkin, is enriched in mitochondrial fractions, and the fission protein Drp1 shows modest enrichment [55]. Treatment with the mitochondrial fission inhibitor Mdivi-1 decreases caspase cleavage, suggesting that mitochondrial fission contributes to apoptosis of infected cells [55]. These mitochondrial alterations likely contribute to the neuronal damage observed in VEEV encephalitis.

Within-Host Evolution and Genetic Diversity

The high mutation rate of VEEV’s RNA-dependent RNA polymerase enables rapid adaptation to selective pressures within the host. Deep spatial profiling of VEEV TC-83 in the brains of mice over 7 days post-infection reveals that viral genetic diversity expands over time, peaking at 5 days post-infection, with nonsynonymous mutations accumulating in response to neuroinflammation and immune pressure [7]. The pro-inflammatory response and influx of immune cells correlate with substantial neuronal damage and increased activation of microglia and astrocytes, suggesting that progressive neuroinflammation acts as a selective pressure driving viral evolution [7]. The microenvironment also influences the trajectory of antiviral

Epidemiology and Transmission Dynamics of Venezuelan Equine Encephalitis Virus

Venezuelan equine encephalitis virus (VEEV) represents a complex of antigenically related alphaviruses within the family Togaviridae that circulate in enzootic and epizootic transmission cycles throughout the Americas. The epidemiological landscape of VEEV is defined by a dynamic interplay between genetically distinct viral subtypes, diverse mosquito vectors, vertebrate reservoir hosts, and susceptible equine and human populations. Understanding these transmission dynamics is critical for predicting outbreaks, implementing surveillance, and developing effective veterinary and public health countermeasures.

Classification and Geographic Distribution of VEEV Subtypes

The VEEV serocomplex is classified into six subtypes (I through VI), with subtype I further divided into multiple serotypes (IAB, IC, ID, IE, IF) [3, 20]. This genetic diversity underpins distinct epidemiological behaviors. The epizootic/epidemic subtypes IAB and IC are responsible for the most dramatic outbreaks, characterized by high viremia in equids, which serve as amplification hosts, and subsequent spillover to humans [3, 20, 35]. In contrast, enzootic subtypes (ID, IE, and subtypes II–VI) circulate persistently in sylvatic cycles involving rodent reservoirs and mosquito vectors, causing sporadic human and equine cases without large-scale epizootics [3, 9, 20]. Subtype II, known as Everglades virus (EVEV), is endemic to Florida, USA, and is maintained in a distinct enzootic cycle [9]. Subtype IIIA, Mucambo virus (MUCV), circulates in the Brazilian Amazon, where seroprevalence in humans and wild vertebrates can exceed 57% and 61%, respectively, indicating intense enzootic activity [17]. The geographic range of VEEV extends from the southern United States through Central America and into South America, with evidence of circulation in Costa Rica, Panama, Colombia, Peru, Guatemala, and Brazil [1, 3, 9, 13, 17, 37, 57, 58, 68]. Phylogenetic analyses of subtype IE strains from Costa Rica suggest ancestral lineages originating from Nicaragua and Guatemala, highlighting the historical connectivity of VEEV populations across Central America [3]. Recent isolations of subtype IE from a spider monkey in Guatemala in 2023 underscore the ongoing circulation and the potential for geographic expansion [57].

Enzootic Transmission Cycles: Vectors, Reservoirs, and Maintenance

The enzootic cycle of VEEV is a highly specialized system involving mosquito vectors of the subgenus Culex (Melanoconion) and small mammals, primarily rodents of the subfamily Sigmodontinae [9, 20]. The Spissipes section of Culex (Melanoconion), including species such as Cx. pedroi, Cx. spissipes, Cx. panocossa, and Cx. cedecei, are the principal enzootic vectors [9, 15]. These mosquitoes exhibit specific habitat preferences, often associated with tropical forests, mangroves, and wetlands, and their feeding behavior is critical for virus maintenance. For example, in Florida, Cx. cedecei is the only confirmed vector for EVEV, based on high natural infection rates, efficient vector competence, and frequent feeding on muroid rodents [9]. Effective surveillance of these vectors requires tailored trapping methods, as no single trap is optimal for all species or physiological states; the mosquito drift fence and pop-up resting shelters have proven effective for collecting blood-engorged females of different Melanoconion species in Panama and Florida [15].

The primary vertebrate reservoirs for enzootic VEEV are wild rodents, particularly hispid cotton rats (Sigmodon hispidus) and cotton mice (Peromyscus gossypinus) for EVEV in Florida [9]. These rodents develop sufficient viremia to infect feeding mosquitoes and maintain the virus in nature. However, recent evidence has expanded the potential host range. Frugivorous bats, specifically Artibeus planirostris and Sturnira lilium, have been found to harbor VEEV RNA and antigens in brain, spleen, and lung tissues in Colombia, suggesting they may serve as accidental or potentially amplifying hosts in certain ecosystems [13, 20, 45]. The detection of VEEV in bats, combined with their mobility and roosting behavior, introduces a potential mechanism for long-distance viral dispersal and bridging into peridomestic environments [13, 45]. The enzootic cycle is further characterized by the detection of VEEV complex RNA in Culex (Melanoconion) vomerifer pools in Panama, which led to virus isolation and phylogenetic confirmation of the ID subtype [24]. In the Brazilian Amazon, genomic fragments of MUCV (subtype IIIA) were detected in pools of Uranotaenia geometrica, indicating that even less-studied mosquito genera may play a role in enzootic maintenance [17].

Epizootic/Epidemic Emergence: Amplification and Spillover

The transition from enzootic to epizootic transmission is a hallmark of VEEV epidemiology and represents a significant threat to equine and human health. Epizootic strains (IAB and IC) are believed to arise from enzootic progenitors, most likely subtype ID, through a limited number of key mutations that enhance viremia in equids [3, 9, 20]. This genetic shift allows horses and other equids to become amplification hosts, developing viremia titers sufficient to infect a wide range of mosquito vectors, including epizootic species such as Aedes taeniorhynchus [9]. The resulting amplification cycle leads to explosive outbreaks involving thousands of equine and human cases. The 1995 outbreak in Colombia and Venezuela, caused by subtype IC, is a classic example, with an estimated 75,000 human cases and significant equine mortality [20]. The risk of epizootic emergence is particularly concerning for EVEV in Florida, as its closest genetic relative is the enzootic subtype ID, and the abundance of Ae. taeniorhynchus in southern Florida provides a conducive environment for widespread transmission should epizootic mutations arise [9].

Human infection typically occurs as a spillover event from the equine amplification cycle, although direct mosquito-to-human transmission from enzootic cycles also occurs, particularly in rural and forested areas [1, 20]. The clinical presentation in humans ranges from a self-limiting febrile illness to severe encephalitis, with children being at highest risk for neurological disease and death [20, 47]. In Panama, analysis of 168 human alphavirus encephalitis cases from 1961 to 2023 revealed that VEEV and Madariaga virus (MADV) are significant causes of neurological disease, with clinical signs often indistinguishable from other arboviral infections like dengue, complicating diagnosis [1]. In the Peruvian Amazon, screening of 1,972 febrile patients in 2020–2021 detected a 3.9% neutralizing antibody prevalence and two PCR-positive cases, confirming ongoing endemic transmission [58]. Similarly, in Costa Rica, a national seroprevalence study in horses found a 36% seroprevalence for VEEV, indicating widespread exposure, while EEEV seroprevalence was only 3%, highlighting the dominant role of VEEV in the region [37].

Transmission Dynamics and Routes of Infection

VEEV is primarily transmitted through the bite of an infected mosquito. However, the virus is also highly infectious via the aerosol route, a feature that has led to its classification as a Category B select agent and a biodefense concern [25, 60, 61, 64, 65]. Aerosol transmission is a critical consideration for laboratory accidents and potential bioterrorism, and it is the primary route used in animal models for vaccine and therapeutic evaluation [60, 61, 64, 65]. The infectious dose for nonhuman primates via aerosol is remarkably low, with an ID50 of approximately 12 PFU for subtype IC and 6.7 PFU for subtype IAB, emphasizing the high infectivity of this route [64].

Following intranasal exposure, VEEV can enter the central nervous system (CNS) directly via olfactory sensory neurons (OSNs) [2, 11]. Immature OSNs, which express higher levels of the VEEV entry receptor LDLRAD3, are the initial targets of infection in the nasal cavity [2, 5, 11, 18]. This neuroinvasion pathway is remarkably rapid, and the host interferon response in the olfactory neuroepithelium and olfactory bulb is delayed for up to 48 hours, providing a critical window for therapeutic intervention [2, 11]. The LDLRAD3 receptor is not only essential for entry into OSNs but is also required for efficient peripheral infection and neurotropism in mice; Ldlrad3-deficient mice survive both intranasal and intracranial VEEV challenge, demonstrating that this receptor is a key determinant of pathogenesis [5]. The structural basis of this interaction has been elucidated through cryo-electron microscopy, showing that domain 1 of LDLRAD3 binds to a cleft between adjacent E2-E1 heterodimers on the viral spike [14].

Once systemic infection is established, VEEV replicates in lymphoid tissues before invading the CNS. The blood-brain barrier (BBB) plays a critical role in this process. VEEV infection induces BBB permeability through mechanisms involving matrix metalloproteinases (MMPs) and toll-like receptor 4 (TLR4) signaling [19]. In C3H mice, TLR4-defective mice (C3H/HeJ) survive intranasal infection with VEEV TC-83, while TLR4-competent mice succumb, correlating with reduced BBB permeability and lower levels of MMP-9, MMP-2, ICAM-1, CCL2, and IFN-γ in the brains of TLR4-defective mice [19]. This indicates that TLR4-mediated inflammation is a driver of BBB breakdown and disease severity, independent of viral titers [19]. Within the brain, VEEV exhibits a distinct spatial and temporal pattern of replication. Deep spatial profiling of VEEV TC-83 in mouse brains revealed that viral replication increases throughout the brain until 5–6 days post-infection, with neurons as the primary site of infection [7]. This is accompanied by a robust pro-inflammatory response, influx of immune cells, and neuronal damage, with the olfactory bulb and midbrain/thalamus showing the greatest pathology [7, 23]. Importantly, VEEV can persist in the CNS. In cynomolgus macaques exposed to aerosolized VEEV, viral genomic RNA and pro-inflammatory cytokines were detected in the brain, cerebrospinal fluid, and cervical lymph nodes for more than four weeks after infection, suggesting long-term inflammatory sequelae [62]. In mice lacking functional αβ T-cells, the vaccine strain TC-83 causes persistent brain infection for up to 92 days, providing a model for studying chronic alphaviral neuroinflammation [69].

Ecological Drivers and Emerging Threats

The epidemiology of VEEV is increasingly influenced by anthropogenic and environmental changes. Deforestation, agricultural expansion, and urbanization bring humans and equids into closer contact with enzootic vectors and reservoir hosts, increasing the risk of spillover [9, 20]. Climate change is altering the distribution and abundance of mosquito vectors, potentially expanding the geographic range of VEEV transmission [9, 27]. In Florida, the establishment of Culex panocossa, a vector for EVEV, and the ongoing Everglades restoration project are expected to influence transmission dynamics [9]. The decline of mammal communities due to invasive species like the Burmese python may also alter host-vector interactions [9]. Environmental niche modeling for Costa Rica has identified key bioclimatic variables, mean temperature of the coldest quarter, precipitation of the driest quarter, and annual mean temperature, that predict areas with high propensity for VEEV presence, providing a tool for targeted surveillance [67].

The genetic evolution of VEEV within its transmission cycles is a continuous process. Codon usage bias analysis indicates that VEEV has a low codon usage bias and has undergone translational selection to adapt to its human and equine hosts, suggesting ongoing co-evolution [59]. Within-host evolution during brain infection has been documented, with an expansion of genetic diversity and nonsynonymous mutations peaking by 5 days post-infection, driven by selective pressures from neuroinflammation [7]. The emergence of antiviral resistance is also influenced by the cellular microenvironment, as demonstrated by the differential trajectory of resistance mutations to the inhibitor ML336 in kidney epithelial versus astrocyte cell lines [66]. These evolutionary dynamics underscore the need for robust surveillance and the development of countermeasures that target conserved viral components or host factors with a high genetic barrier to resistance [63, 66].

Seroprevalence and Surveillance Data

Serological surveys provide critical insights into the true burden of VEEV infection, as clinical cases often represent only a fraction of infections. In Costa Rica, a national equine serosurvey using PRNT80 revealed a VEEV seroprevalence of 36%, with altitude below 100 meters identified as a significant risk factor [37]. In the Peruvian Amazon, a 3.9% neutralizing antibody prevalence in febrile patients indicates substantial past exposure [58]. In the Brazilian Amazon, MUCV seroprevalence reached 57.3% in humans and 61.5% in wild vertebrates, demonstrating intense enzootic circulation [17]. In Panama, real-time RT-PCR assays have been validated for surveillance, detecting VEEV complex RNA in 66.7% of retrospective outbreak samples and in 11.9% of patients presenting with dengue-like illness, highlighting the diagnostic challenges and the need for molecular surveillance in endemic regions [24]. The development of sensitive detection methods, such as magnetic Nanotrap particles that preserve VEEV stability in blood at elevated temperatures, facilitates field-based surveillance and sample transport [12]. These data collectively indicate that VEEV is a widely distributed and underdiagnosed pathogen, with significant implications for both veterinary and public health.

Clinical Manifestations and Pathology in Horses and Other Susceptible Species

The clinical trajectory of Venezuelan equine encephalitis virus (VEEV) infection is inextricably linked to viral subtype, host immune status, and route of inoculation, yet the most dramatic and economically consequential manifestations occur in equids. Horses serve as the primary amplifying hosts during epizootic cycles, exhibiting a disease course that is both rapidly progressive and frequently fatal. The incubation period in naturally infected horses typically ranges from one to five days following the bite of an infected mosquito from the Culex (Melanoconion) subgenus, after which a biphasic febrile illness ensues [3, 20, 27]. The initial febrile phase, characterized by temperatures reaching 39.5–41°C, corresponds to the period of peak viremia, which in horses can exceed 10⁹ plaque-forming units per milliliter of blood, a titer sufficiently high to infect feeding mosquitoes and thus perpetuate epizootic transmission [20, 27]. This profound viremia distinguishes the epizootic subtypes (IAB and IC) from their enzootic counterparts and is the biological basis for the horse’s role as a sentinel and amplifier [3, 35].

Clinical progression during the first 24–48 hours often includes depression, anorexia, and prostration, with some animals exhibiting a stiff gait or muscle fasciculations that herald central nervous system (CNS) involvement [27, 37]. As the virus invades the neuroparenchyma, neurological signs become apparent: hyperexcitability, ataxia, circling, head pressing, blindness, and recumbency are frequently documented. Seizures and nystagmus may also develop, reflecting the predilection of VEEV for the thalamus, midbrain, and olfactory regions [23, 27, 32]. Mortality rates in naïve equine populations can approach 50–80% during epizootics, with death often occurring within 5–10 days of the onset of neurological signs [22, 37]. Survivors may experience persistent neurological sequelae, including cognitive deficits and gait abnormalities, although systematic long-term follow-up studies in horses remain sparse. Importantly, the Costa Rican isolate from a mare with severe encephalitis, which grouped within the Pacific cluster of subtype IE, underscores that even enzootic lineages can induce lethal neurological disease in individual animals, albeit with lower epizootic potential [3, 68].

Neuropathogenesis and Lesion Distribution

The neuropathology of VEEV in horses mirrors that observed in experimental murine and nonhuman primate models, albeit with species-specific nuances in lesion topography and inflammatory intensity. Upon entry into the CNS, facilitated by both hematogenous seeding across a compromised blood-brain barrier (BBB) and direct axonal transport within olfactory sensory neurons, VEEV exhibits a marked tropism for neurons [2, 5, 11, 18]. Postmortem examination of equine brains reveals a non-suppurative meningoencephalomyelitis with perivascular cuffing, gliosis, and neuronal necrosis, particularly within the cerebral cortex, thalamus, hippocampus, and brainstem [3, 25, 68]. The olfactory bulb is frequently among the earliest and most severely affected structures, consistent with the neuroinvasive pathway documented in murine intranasal challenge models where immature olfactory sensory neurons expressing high levels of the LDLRAD3 receptor serve as the initial portal of entry [2, 5, 11]. Immunohistochemical staining of brain sections from infected horses demonstrates abundant viral antigen within the cytoplasm of neurons and, to a lesser extent, within glial cells, corroborating the neuronal tropism established through receptor-mediated entry [5, 14, 18].

In murine models, which remain the most extensively characterized experimental system, the progression of neuropathology follows a stereotyped temporal and spatial pattern. Intranasal inoculation of C3H/HeN mice with VEEV TC-83 results in a time-dependent increase in neuroinflammation, apoptosis, and hypoxia across multiple brain regions, as visualized through positron emission tomography (PET) imaging with tracers targeting translocator protein (TSPO), caspase-3 activity, and fluormisonidazole retention [32]. The olfactory bulb demonstrates a sharp increase in [¹⁸F]DPA-714 uptake by day 3 post-infection, peaking at day 7, while the cortex, thalamus, striatum, and hippocampus exhibit a more delayed but sustained inflammatory signal that persists through day 10 [32]. This regional heterogeneity in neuroinflammatory burden correlates closely with viral RNA distribution; deep spatial profiling of VEEV TC-83 in mouse brains has revealed that viral replication increases throughout the brain until 5–6 days post-infection, with neurons serving as the principal sites of replication, and that the pro-inflammatory response and immune cell influx mirror the viral load [7]. Critically, this same study documented an expansion in the genetic diversity of VEEV within the brain over the course of infection, with nonsynonymous mutations peaking by day 5, suggesting that progressive neuroinflammation itself may act as a selective pressure driving within-host viral evolution [7].

Cellular and Molecular Pathology

At the cellular level, VEEV infection induces a cascade of degenerative processes that culminate in neuronal death through both apoptotic and necrotic mechanisms. The unfolded protein response (UPR) is activated early during infection, with the protein kinase RNA-like endoplasmic reticulum kinase (PERK) arm driving the upregulation of activating transcription factor 4 (ATF4) and the pro-apoptotic transcription factor CHOP (DDIT3) [53, 56]. This PERK-dependent signaling cascade subsequently induces expression of early growth response 1 (EGR1), a transcription factor that modulates the expression of numerous pro-apoptotic genes. In primary human astrocytes, EGR1 upregulation is dependent on both ERK1/2 and PERK signaling, and siRNA-mediated knockdown of EGR1 significantly reduces VEEV-induced apoptosis while also impacting viral replication [53]. Embryonic fibroblasts derived from EGR1 knockout mice demonstrate markedly lower susceptibility to VEEV-induced cell death compared to wild-type cells, underscoring the critical role of this transcription factor in the neurovirulence of the virus [56]. Furthermore, VEEV infection triggers profound alterations in mitochondrial dynamics, including a robust drop in mitochondrial activity, perinuclear accumulation of mitochondria, and enrichment of the damage-associated kinases PINK1 and Parkin in mitochondrial fractions [55]. The fission mediator Drp1 is also enriched in mitochondrial fractions, and pharmacological inhibition of mitochondrial fission with Mdivi-1 decreases caspase cleavage, indicating that mitochondrial fragmentation contributes to the apoptotic cascade in infected neural cells [55].

The capsid protein of VEEV functions as a primary virulence factor, exerting pleiotropic effects on host cell physiology that extend well beyond its structural role. VEEV capsid inhibits host cell transcription, blocks nucleocytoplasmic trafficking through its interaction with the importin α/β1 heterodimer and CRM1, and delays cell cycle progression at the G0/G1 phase [36, 38, 42, 43]. This cell cycle arrest is dependent on the capsid nuclear localization signal (NLS), as infection with a virus encoding an NLS mutant partially rescues cell cycle dysregulation and restores expression of key cyclins, including cyclin D1, cyclin A2, and cyclin E2 [42]. The capsid protein also undergoes phosphorylation at multiple residues, a modification regulated by protein kinase Cδ (PKCδ) and protein phosphatase 1α (PP1α). Phosphorylation status modulates capsid-RNA binding affinity and, consequently, viral assembly and particle infectivity [29, 41]. A mutant virus in which capsid phosphorylation sites were replaced with alanine (VEEV CPD) exhibited a lower genomic copy-to-PFU ratio, indicating more efficient assembly and release of infectious particles, yet paradoxically this mutant was attenuated in a mouse model, with increased survival and reduced clinical signs relative to parental virus [29]. These observations highlight the exquisite balance between replication efficiency and pathogenesis that is governed by capsid phosphorylation.

Blood-Brain Barrier Disruption and Inflammatory Mediators

The integrity of the BBB is severely compromised during VEEV encephalitis, a process mediated in large part by matrix metalloproteinases (MMPs) and toll-like receptor 4 (TLR4) signaling. In the C3H murine model, intranasal infection with VEEV TC-83 leads to increased BBB permeability as measured by sodium fluorescein and fluorescently conjugated dextran extravasation, and this effect is markedly attenuated in TLR4-defective C3H/HeJ mice [19]. Infected TLR4-defective mice also exhibit significantly lower levels of MMP-9, MMP-2, ICAM-1, CCL2, and IFN-γ in the brain compared to TLR4-competent mice, despite equivalent viral titers, demonstrating that TLR4 signaling drives BBB dysfunction and disease severity independent of viral load [19]. Complementary studies using a human blood-brain barrier organ-on-a-chip model have confirmed that VEEV infection damages the endothelial lining and that therapeutic intervention with the NRF2 activator omaveloxolone can preserve BBB integrity while reducing viral and inflammatory burden [47, 49]. The transcriptomic reprogramming induced by omaveloxolone, shifting the host response from an interferon-centric, pro-inflammatory state toward an NRF2-driven antioxidant and cytoprotective program while preserving core antiviral mechanisms, represents a promising therapeutic paradigm for mitigating the neurovascular damage that underpins VEEV encephalitis [47].

The chemokine and cytokine milieu within the infected CNS is a critical determinant of both antiviral defense and immunopathology. TNF-α, CCL-2, and CCL-5 levels in the brain correlate strongly with histopathological severity in lethally infected mice, and principal component analysis has identified a clear correlation between specific brain inflammation and clinical signs of disease [23]. In the cynomolgus macaque model, aerosol exposure to VEEV results in high levels of MCP-1 (CCL2) and IP-10 (CXCL10) in the CNS by day 6 post-infection, accompanied by marked infiltration of T lymphocytes and activated microglia [62]. Notably, viral genomic RNA persists in the brain, cerebrospinal fluid, and cervical lymph nodes for more than four weeks after resolution of acute disease, and pro-inflammatory cytokines, infiltrating leukocytes, and pathological changes are still evident at these later time points, suggesting that VEEV infection can establish a chronic inflammatory focus within the CNS [62]. This finding has profound implications for survivors of VEEV encephalitis, as persistent neuroinflammation may contribute to long-term neurological sequelae, including cognitive dysfunction and psychiatric disorders, that are increasingly recognized following infections with neurotropic viruses.

Pathology in Non-Equine Susceptible Species

While horses and humans are the primary clinically relevant hosts, VEEV infects a broad range of vertebrate species that serve as either reservoir hosts or accidental targets. In the enzootic cycle, muroid rodents, particularly hispid cotton rats (Sigmodon hispidus) and cotton mice (Peromyscus gossypinus), are the principal vertebrate reservoirs for Everglades virus (subtype II) and for enzootic subtypes ID, IE, and IF in Central and South America [9, 17, 20]. These rodents typically develop high-titer viremia sufficient to infect naïve mosquito vectors without exhibiting overt clinical signs, enabling silent circulation of the virus in sylvatic habitats. However, experimental infections of cotton rats have demonstrated that neuroinvasion and encephalitis can occur, particularly in juvenile animals or under conditions of high inoculum, raising the possibility that rodent mortality may influence enzootic transmission dynamics in ways not fully appreciated [9, 17].

Frugivorous bats have recently emerged as a potential reservoir or incidental host of VEEV in Latin America. In Colombia, immunohistochemical and molecular detection of VEEV antigen in brain, spleen, and lung tissues of Artibeus planirostris and Sturnira lilium provided the first cellular and molecular evidence of natural VEEV infection in bats [13, 45]. Histopathological examination of these tissues revealed mild to moderate inflammatory changes, but the bats were captured in apparently healthy condition, suggesting that they may sustain subclinical infections capable of contributing to viral maintenance [13]. The detection of neutralizing antibodies against VEEV subtype IIIA (Mucambo virus) in 61.5% of wild vertebrates sampled in the Brazilian Amazon further underscores the breadth of the sylvatic host range and the complexity of the enzootic transmission network [17].

Nonhuman primates (NHPs) are highly susceptible to VEEV and develop a disease syndrome that closely recapitulates human infection. Cynomolgus macaques exposed to small-particle aerosols containing VEEV IC subtype develop a biphasic fever with maximum temperature deviation correlating to inhaled dose, followed by neurological signs predominantly during the second febrile period [62, 64]. Electroencephalography reveals a statistically significant decrease in all power bands and circadian index during the second febrile phase, and intracranial pressure increases late in this period, mirroring the clinical picture of human encephalitis [62]. The infectious dose fifty (ID₅₀) for macaques is remarkably low, approximately 12 PFU for subtype IC and 6.7 PFU for subtype IAB, indicating that aerosolized VEEV is among the most infectious viral pathogens for primates [64]. Pathological examination of NHP brains reveals lymphocytic meningoencephalitis with perivascular cuffing, microglial nodules, and neuronal loss distributed throughout the olfactory bulb, neocortex, thalamus, and brainstem [61, 62, 71]. Intriguingly, a recent report of VEEV subtype IE isolation from a spider monkey (Ateles geoffroyi) in Guatemala, phylogenetically related to Gulf Coast strains, confirms that nonhuman primates in the Neotropics are naturally exposed and can develop productive infections, thereby warranting intensified surveillance of VEEV transmission cycles in North America [57].

Comparative Pathology and Prognostic Indicators

Across species, the severity of neurological disease correlates with the magnitude and duration of viremia, the efficiency of CNS invasion, and the intensity of the host inflammatory response. In horses, a rapidly rising viremia that exceeds 10⁶ PFU/mL is a poor prognostic indicator, and the presence of lymphopenia, a hallmark of VEEV infection in both horses and NHPs, reflects systemic immune dysregulation [27, 64]. In mice, biomarkers such as TNF-α, CCL-2, and CCL-5 demonstrate stronger correlations with histopathological severity than viral titers themselves, suggesting that the host inflammatory response is the primary driver of tissue damage and clinical outcome [23]. This observation has guided therapeutic strategies that seek to dampen deleterious inflammation while preserving antiviral immunity; the combination of neutralizing antibodies with intact Fc effector functions has proven superior to neutralization alone in extending the therapeutic window post-exposure in murine models [70]. In NHPs, administration of the chimeric monoclonal antibody c1A3B-7 as late as 48 hours after aerosol exposure significantly reduced viremia, fever, and lymphopenia, demonstrating that post-exposure immunotherapy can modify disease course even after CNS invasion has begun [71].

The role of host genetics in susceptibility and pathogenesis is increasingly appreciated. Mice with defective TLR4 signaling survive otherwise lethal VEEV infection despite equivalent brain viral loads, highlighting the centrality of innate immune signaling in neuropathogenesis [19]. Similarly, transgenic mice lacking the VEEV entry receptor LDLRAD3 are completely protected from intranasal and intracranial inoculation, confirming that receptor expression is a non-redundant determinant of neurotropism and disease [5, 18]. These findings have immediate translational relevance, as soluble LDLRAD3 decoy proteins and receptor-targeted antibodies represent plausible prophylactic and therapeutic interventions for both human and equine populations [14, 18]. Furthermore, the relative resistance of certain equine breeds or individuals to VEEV encephalitis has been anecdotally reported but remains poorly characterized; systematic genetic association studies using modern genomic tools could identify protective alleles that inform breeding strategies and risk assessment in endemic regions.

Diagnostic Approaches for Venezuelan Equine Encephalitis Virus Infection

The accurate and timely diagnosis of Venezuelan equine encephalitis virus (VEEV) infection in equids and, by extension, in humans and other susceptible species, presents a formidable challenge that sits at the intersection of clinical suspicion, advanced molecular biology, serological surveillance, and strict biosafety protocols. Given that VEEV is a WOAH-listed disease and a recognized select agent with potential for aerosol dissemination, diagnostic approaches must be robust enough to differentiate it from other causes of encephalitis, sensitive enough to detect low-level viremia during the acute phase, and specific enough to discriminate between the enzootic (subtypes ID-IF, II-VI) and epizootic (IAB, IC) strains that dictate outbreak potential [3, 9, 20]. The following section delineates the comprehensive armamentarium available for VEEV diagnosis, from initial clinical assessment through to confirmatory laboratory testing, emphasizing the critical importance of assay selection based on disease stage, sample integrity, and the specific objective of the investigation.

Clinical Recognition and Differential Diagnosis

The initial diagnostic step for VEEV infection rests on a high index of clinical suspicion, particularly in endemic regions of Central and South America, Florida (for Everglades virus, subtype II), and Trinidad [1, 9, 37]. Equids typically present with a biphasic febrile illness following an incubation period of 1–5 days. The first phase is characterized by pyrexia, anorexia, and leukopenia, often accompanied by a transient viremia that is critical for mosquito-borne transmission [27, 64]. The second phase, occurring in a subset of animals, involves central nervous system (CNS) invasion, manifesting as ataxia, hyperexcitability, circling, head pressing, paralysis, and ultimately, seizures or coma [3, 27]. The case fatality rate in equids can reach 50–90% for epizootic strains, underscoring the urgency of early detection [22, 25].

However, clinical signs alone are insufficient for a definitive diagnosis. VEEV encephalitis is clinically indistinguishable from other arboviral encephalitides, including those caused by Eastern equine encephalitis virus (EEEV), Western equine encephalitis virus (WEEV), and even flaviviruses such as West Nile virus (WNV) [27]. Furthermore, the initial febrile phase mimics common tropical infections like dengue, Zika, and chikungunya, creating a substantial diagnostic dilemma in resource-limited settings [1, 20]. A study of human cases in Panama over six decades highlighted that symptoms such as fever, headache, and myalgia were non-specific predictors, and only progression to frank neurological signs reliably distinguished alphavirus encephalitis from other arboviral diseases [1]. Therefore, clinical diagnosis must be supported by robust laboratory evidence, and any acute febrile illness with neurological progression in a horse or human from an endemic area should trigger immediate diagnostic testing for VEEV.

Molecular Diagnostics: Reverse Transcription Polymerase Chain Reaction (RT-PCR)

The gold standard for confirming acute VEEV infection is the detection of viral RNA via reverse transcription polymerase chain reaction (RT-PCR). This approach is most effective during the early, viremic phase of illness, typically within the first 1–4 days post-onset of fever, before the development of neutralizing antibodies clears the virus from the bloodstream [24, 58]. Real-time RT-PCR (rRT-PCR) assays have been designed to target conserved regions of the viral genome, such as the nonstructural protein 4 (nsP4) gene or the E2 envelope glycoprotein gene, allowing for pan-VEEV complex detection or specific subtype identification [13, 17, 24].

A validated, multi-target rRT-PCR panel developed for use in Panama and other endemic regions has demonstrated high sensitivity, successfully detecting VEEV complex RNA in retrospectively confirmed outbreak samples and prospectively in suspected dengue cases that were, in fact, VEEV infections [24]. This assay was capable of differentiating VEEV complex from Madariaga virus (MADV) and EEEV, a critical feature given their overlapping geographic ranges and clinical presentations [24]. Furthermore, molecular assays have been successfully applied to environmental surveillance, detecting VEEV RNA in mosquito pools, specifically Culex (Melanoconion) species such as Cx. vomerifer and Cx. pedroi, which is essential for understanding transmission dynamics and predicting outbreak risk [15, 24].

Sample quality is paramount for molecular diagnostics. VEEV genomic RNA is labile, and degradation during transport in warm climates can lead to false negatives. Innovative stabilization techniques, such as the use of magnetic Nanotrap® (NT) particles, have been shown to preserve viral RNA and capsid protein integrity in whole blood samples stored at elevated temperatures (40°C) for up to 72 hours [12]. This technology is particularly valuable for field collection in remote tropical regions where cold-chain logistics are challenging. It is also important to note that VEEV is a positive-sense single-stranded RNA virus; the extracted RNA itself is potentially infectious if introduced into permissive cells [16]. To safely remove samples from high-containment (BSL-3) laboratories, validated inactivation methods, such as RNA fragmentation or successful cDNA synthesis, must be employed to render the genome non-infectious before downstream analysis [16].

Sequencing of RT-PCR products or whole viral genomes provides additional phylogenetic and epidemiological insights. Deep sequencing of VEEV from brain tissue has revealed a high degree of within-host genetic diversity, with non-synonymous mutations accumulating during neuroinvasion and neuroinflammation, which may have implications for virulence and therapeutic resistance [7]. Phylogenetic analyses have traced the origins of epizootic IAB and IC strains from enzootic ID ancestors, and have documented the emergence of subtype IE strains in Costa Rica and Guatemala, demonstrating the continuous evolution of the virus [3, 57, 58].

Serological Approaches: Plaque Reduction Neutralization Testing (PRNT) and ELISA

Serology remains the mainstay for diagnosing VEEV infection in convalescent animals and for conducting seroprevalence studies to assess exposure in populations. The most specific and widely accepted serological test for VEEV is the plaque reduction neutralization test (PRNT), particularly the PRNT80 (80% reduction) variant [37, 73]. PRNT is considered the reference standard due to its ability to differentiate VEEV from other closely related alphaviruses, such as EEEV and WEEV, by measuring functional neutralizing antibodies against the E2 glycoprotein [37, 60, 72]. In a cross-sectional study of Costa Rican horses, PRNT80 revealed a 36% seroprevalence for VEEV, compared to only 3% for EEEV, highlighting the endemicity of VEEV and the specificity of this test [37].

However, PRNT requires the use of live, infectious virus, necessitating BSL-3 containment for epizootic strains. For field-based or lower-containment settings, enzyme-linked immunosorbent assays (ELISAs) are often used as screening tools. IgG capture ELISAs detecting antibodies against the E1 or capsid proteins are commonly employed, though they may exhibit cross-reactivity with other alphaviruses and thus require PRNT confirmation [37, 73]. Studies in the Brazilian Amazon have demonstrated that neutralizing antibodies to VEEV subtype IIIA (Mucambo virus) are highly prevalent in wild vertebrates and humans, underscoring the value of serosurveillance in identifying enzootic transmission cycles [17].

An important caveat in serological diagnosis is the timing of antibody appearance. IgM antibodies appear within the first few days of illness and are indicative of recent or acute infection, while IgG antibodies persist for years [20, 25]. In fatal or neurological cases, immunohistochemistry (IHC) on formalin-fixed brain tissue can be used to detect VEEV antigens directly in neurons, providing a definitive post-mortem diagnosis. IHC has been successfully employed to confirm natural VEEV infection in frugivorous bats (Artibeus planirostris and Sturnira lilium) in Colombia, demonstrating its utility for reservoir host surveillance [13, 45].

Virus Isolation and Characterization

Isolation of infectious VEEV from clinical specimens (blood, brain tissue, or mosquito pools) provides definitive proof of infection and is essential for characterizing circulating strains. Isolation is typically performed by inoculating Vero or BHK-21 cell cultures and monitoring for cytopathic effect, followed by confirmation via immunofluorescence or RT-PCR [13, 57, 58]. Virus isolation is critical for generating challenge material for vaccine efficacy studies under the FDA Animal Rule, where well-characterized viral stocks of epizootic IAB and IC strains are required [35]. Whole-genome sequencing of isolates enables the identification of unique mutations, such as those in the E1 and E2 glycoproteins that distinguish epizootic from enzootic subtypes, and provides data for molecular clock analyses [3, 75]. While highly definitive, virus isolation is time-consuming, requires BSL-3 or BSL-4 facilities, and is less sensitive than RT-PCR for samples with low viral loads.

Biosafety Considerations in Diagnostic Workflow

Given its classification as a select agent and its high infectivity via the aerosol route, handling of VEEV diagnostic specimens demands rigorous biosafety precautions. All manipulations of potentially infectious samples, including blood, CSF, and tissues, must be performed in BSL-3 or BSL-4 containment laboratories, depending on the strain [16, 39, 74]. Prior to removal from containment, samples must be inactivated using validated protocols. For molecular assays, this can be achieved through RNA extraction using chaotropic agents like buffer AVL, though it is noteworthy that buffer AVL alone may not fully inactivate high-titer VEEV [74]. A more effective approach involves a two-step inactivation: a chemical step (e.g., glutaraldehyde fixation or SDS treatment) followed by a physical step (e.g., heat inactivation at 60°C for 60 minutes) [74]. For structural studies, glutaraldehyde fixation followed by sucrose cushion purification has been validated to inactivate VEEV while preserving particle morphology for cryo-electron microscopy [39].

Integration into Surveillance and Outbreak Response

The most effective diagnostic strategy for VEEV involves a tiered approach tailored to the epidemiological context. For acute clinical cases, rRT-PCR on whole blood or serum is the method of choice [24, 58]. For seroprevalence surveys or convalescent diagnosis, PRNT or IgG ELISA confirmed by PRNT is standard [37]. For vector surveillance, RT-PCR on mosquito pools is highly sensitive and can be integrated into early warning systems [15, 24]. The identification of neutralizing antibodies in non-human primates, such as the spider monkey (Ateles geoffroyi) in Guatemala, underscores the value of serosurveillance in sentinel animals to detect sylvatic transmission before human or equine cases emerge [57]. Ultimately, a well-coordinated diagnostic pipeline, encompassing clinical recognition, molecular detection, serological confirmation, and phylogenetic characterization, is essential for understanding VEEV eco-epidemiology, guiding vaccination strategies, and implementing rapid outbreak control measures in accordance with WOAH and CDC guidelines.

Therapeutic Strategies and Host-Directed Interventions for Venezuelan Equine Encephalitis Virus

The development of effective countermeasures against Venezuelan equine encephalitis virus (VEEV) remains one of the most pressing challenges in veterinary and zoonotic disease management. Despite decades of research and recognition by global health authorities including the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO), no FDA-approved antiviral therapeutics currently exist for human or equine use [20, 25, 27]. This therapeutic void is particularly alarming given that VEEV is classified as a Category B select agent with documented history of weaponization and high infectivity via aerosol routes [25, 26, 79]. The pathogenic mechanisms underlying VEEV-induced encephalitis involve a complex interplay between direct viral cytopathology and a dysregulated host inflammatory response, suggesting that optimal therapeutic strategies must address both viral replication and the deleterious host consequences of infection [23, 32, 44]. Contemporary research has therefore bifurcated into two complementary approaches: direct-acting antivirals targeting essential viral components, and host-directed interventions that modulate cellular pathways to create an unfavorable environment for viral replication while mitigating immunopathology [47, 78, 81].

Direct-Acting Antiviral Strategies Targeting Viral Replication Machinery

The VEEV nonstructural proteins, particularly nsP1, nsP2, and the RNA-dependent RNA polymerase (nsP4), represent highly attractive targets for direct antiviral intervention due to their essential roles in viral RNA synthesis and capping [6, 10, 22, 46]. The nsP2 cysteine protease is arguably the most extensively characterized drug target, responsible for proteolytic processing of the nonstructural polyprotein and concurrently serving as an interferon antagonist through cleavage of host proteins such as TRIM14 [46, 52]. High-throughput screening and structure-based drug design have yielded several promising inhibitor classes targeting nsP2 protease activity. The epoxysuccinyl prodrug CA074 methyl ester (CA074me) demonstrated remarkable potency in virus yield reduction assays, achieving greater than 5-log reductions in viral titer, with X-ray crystallography confirming that CA074 occupies a distinct binding pocket within the protease [6]. Hybrid inhibitors designed by merging structural elements of E64d and CA074 produced compounds with enhanced activity, notably NCGC00488909-01 exhibiting an EC50 of 1.76 µM against VEEV-TrD and demonstrating time-dependent inhibition kinetics with a Ki of 3 µM [6]. Vinyl sulfone-based nonpeptidic covalent inhibitors have similarly shown promise, with compound 11 achieving EC50 values of 2.4 µM in HeLa cells and 1.6 µM in Vero E6 cells against the virulent Trinidad Donkey strain [77].

Beyond the protease domain, the nsP1 capping enzyme has emerged as a validated target given its unique alphavirus-specific mechanism involving methyltransferase and guanylyltransferase activities essential for viral mRNA cap formation [22, 34]. A high-throughput ELISA-based screening campaign evaluating 1,220 approved compounds identified 18 inhibitors of nsP1 guanylylation, with subsequent characterization confirming selective inhibition of the viral methyltransferase without affecting cellular methyltransferase activity [34]. The benzamidine compound ML336 has been extensively characterized as a potent inhibitor of viral RNA synthesis, demonstrating an IC50 of 1.1 nM for inhibition of VEEV RNA synthesis through interaction with the viral replicase complex, effectively blocking production of positive-sense genomic, negative-sense template, and subgenomic RNAs [54]. Importantly, resistance profiling revealed that ML336 selects for mutations in nsP2 and nsP4, and the trajectory of resistance emergence is profoundly influenced by the cellular microenvironment, with distinct single nucleotide polymorphism profiles emerging in Vero versus astrocyte cell lines [66]. Quinolinone compounds identified through cell-based screening provide additional therapeutic options, with resistance mapping to residue Y102 in the helicase stalk domain of nsP2, and reverse genetics experiments demonstrating that introduction of K102Y into chikungunya virus (CHIKV) nsP2 enhances sensitivity to this chemical series [51].

The viral structural proteins have also yielded to structure-guided inhibitor design. The E1 fusion glycoprotein interacts with the cellular chaperone protein disulfide isomerase A6 (PDIA6), and pharmacological inhibition of protein disulfide isomerases (PDIs) using LOC14 or the FDA-approved anti-protozoal agent nitazoxanide effectively reduced production of VEEV and other alphaviruses by impairing disulfide bond formation within E1 and disrupting both early and late replication events [8]. Resveratrol, a natural phytochemical, demonstrates dual activity by inhibiting the host AKT/GSK-3 pathway essential for VEEV replication while simultaneously binding directly to viral glycoproteins, potentially interfering with attachment and entry [76]. Targeting the viral capsid protein (CP), which uniquely among alphaviruses traffics to the nucleus to shut down host transcription, represents another innovative strategy [38, 42]. In silico structure-based drug design screening of 1.5 million compounds identified inhibitors of the importin α/β1:CP interaction, with compound G281-1564 demonstrating low micromolar antiviral activity and confirmed inhibition of CP nuclear accumulation in infected cells [43]. A parallel high-throughput screening campaign for the same host-virus interface yielded additional leads with robust antiviral activity and minimal cytotoxicity, validating the principle that disrupting CP nucleocytoplasmic trafficking can potently suppress VEEV replication [36].

Host-Directed Interventions: Modulating Cellular Signaling and Innate Immunity

Given the propensity of RNA viruses to develop resistance against direct-acting antivirals, host-directed therapies that target cellular pathways exploited by VEEV offer the advantage of a high genetic barrier to resistance and potential broad-spectrum activity [47, 78, 81]. The host-directed strategy is particularly compelling for VEEV because the virus actively subverts interferon signaling and induces a proapoptotic, proinflammatory state that contributes substantially to neuropathogenesis [23, 53, 56].

Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) Activation. The most advanced host-directed therapeutic candidate is omaveloxolone (OMA), an FDA-approved NRF2 activator that has been extensively evaluated in the context of VEEV infection [47, 49]. Transcriptomic profiling of human umbilical vein endothelial cells infected with VEEV TC-83 revealed that untreated infection induced a canonical interferon-stimulated gene (ISG) signature including IFIT1-3, OASL, RSAD2, and MX1, accompanied by robust proinflammatory cytokine and chemokine signaling (IL6, CXCL10, CXCL11) [47]. In striking contrast, OMA treatment redirected the host transcriptional response toward an NRF2-driven cytoprotective program characterized by upregulation of HMOX1, NQO1, GCLM, TXNRD1, and SLC7A11, with 729 genes upregulated and 1,264 downregulated. Critically, cross-comparison using Cross-MAS analysis revealed that OMA preserved a compact 34-gene interferon-centered antiviral backbone while repressing the broader inflammatory cascade, including widespread suppression of histone cluster genes [47]. Network analyses confirmed that OMA-induced NRF2-driven antioxidant modules replaced the cytokine-chemokine modules dominant in untreated infection, suggesting that NRF2 activation may simultaneously limit oxidative damage, ferroptosis, and excessive neuroinflammation while maintaining essential antiviral defenses. This therapeutic approach was further validated in a human blood-brain barrier (BBB) organ-on-a-chip model, where OMA treatment preserved endothelial integrity, decreased viral load, and reduced inflammatory mediators following VEEV infection [49].

Interferon-Based Therapeutics for Olfactory Neuroinvasion. A uniquely promising intervention targets the earliest events in VEEV neuroinvasion, capitalizing on a critical therapeutic window identified within the olfactory pathway [2, 11]. Following intranasal exposure, VEEV initially infects immature olfactory sensory neurons (OSNs) in the olfactory neuroepithelium (ONE), which express high levels of the VEEV entry receptor LDLRAD3. Despite rapid viral neuroinvasion, interferon signaling responses in the ONE and olfactory bulb (OB) are delayed for up to 48 hours, representing a temporal window for intervention [2, 11]. A single intranasal dose of recombinant interferon alpha (IFNα) administered at or shortly after infection triggered robust early ISG expression in both the nasal cavity and OB, transiently suppressing VEEV replication in the ONE and inhibiting subsequent CNS invasion. Treated mice exhibited delayed onset of encephalitic sequelae and extended survival by several days, providing the first evaluation of intranasal IFNα as a post-exposure prophylactic for encephalitic alphavirus exposures [2, 11]. This approach is particularly relevant for biodefense scenarios involving aerosolized VEEV and for natural transmission where nasal mucosal exposure is the primary route.

Modulation of Inflammatory Signaling Pathways. The recognition that VEEV-induced encephalitis is driven as much by immunopathology as by direct viral cytolysis has spurred evaluation of FDA-approved anti-inflammatory drugs as adjunctive therapies [79]. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, demonstrated significant reductions in VEEV TC-83 and Trinidad Donkey titers in astrocyte and microglial models, with 50 µM treatment reducing TrD titers 6.45-fold while concurrently decreasing inflammatory gene expression [79]. Tofacitinib, a Janus kinase (JAK) inhibitor, and rolipram, a phosphodiesterase-4 (PDE4) inhibitor, also showed moderate antiviral activity, suggesting that inflammatory signaling cascades are intimately linked to viral replication efficiency [79]. The toll-like receptor 4 (TLR4) pathway has emerged as a critical mediator of BBB permeability and disease severity during VEEV infection [19]. TLR4-defective C3H/HeJ mice infected intranasally with VEEV TC-83 survived lethal challenge whereas TLR4-sufficient C3H/HeN mice succumbed, despite equivalent viral titers in the brains of both strains. BBB permeability was markedly reduced in TLR4-mutant mice, correlating with diminished matrix metalloproteinase-9 (MMP-9), MMP-2, ICAM-1, CCL2, and IFN-γ levels in the brain [19]. These findings indicate that TLR4 is a druggable target for mitigating VEEV-induced neurovascular pathology.

Small Molecule Kinase Inhibitors and Host Signaling Modulators. The host kinome represents a rich source of therapeutic targets given that VEEV extensively hijacks cellular signaling pathways for its replication. The multi-kinase inhibitor sorafenib, an FDA-approved cancer therapeutic, was identified through high-throughput screening of a library of 2,640 approved drugs and demonstrated broad-spectrum anti-alphavirus activity [81]. Mechanistic studies revealed that sorafenib inhibits viral translation by inducing dephosphorylation of eIF4E and p70S6K, thereby suppressing viral protein production with a selectivity index exceeding 19 in Vero cells [81]. The AKT/GSK-3 pathway is another critical vulnerability; resveratrol-mediated inhibition of this pathway reduced VEEV replication and virion production for at least 48 hours following a single treatment, while also decreasing caspase-3/7 activation and annexin V staining, indicating suppression of virus-induced apoptosis [76]. Protein kinase C delta (PKCδ) phosphorylates the VEEV capsid protein at four residues, regulating viral RNA binding and assembly; siRNA knockdown of PKCδ decreased capsid phosphorylation and viral replication, while a virus with capsid phosphorylation sites mutated to alanine (VEEV CPD) exhibited attenuated pathogenesis in mice with increased survival and reduced clinical signs [29]. Conversely, inhibition of protein phosphatase 1α (PP1α) using the small molecule 1E7-03 decreased VEEV replication by more than 2 logs (EC50 = 0.6 μM) by preventing PP1α-mediated dephosphorylation of capsid, demonstrating that the phosphorylation state of capsid critically governs viral replicative fitness [41].

Host Defense Peptides and Immunomodulatory Agents. Naturally occurring and synthetic host defense peptides (HDPs) offer a unique therapeutic modality that combines direct antiviral activity with immunomodulatory properties [26, 30]. The human cathelicidin peptide LL-37 demonstrated potent antiviral activity against both TC-83 and Trinidad Donkey strains, reducing genomic RNA copies and viral titers through direct viral particle aggregation that prevents entry, while simultaneously upregulating IFNβ1 expression in infected cells [26]. Synthetic peptides derived from indolicidin inhibited VEEV replication by approximately 1,000-fold and decreased expression of IL1α, IL1β, IFNγ, and TNFα at both gene and protein levels, while increasing expression of the anti-inflammatory IL1RN and genes involved in leukocyte chemotaxis [30]. The antiprogestin mifepristone (RU486) and its analogues represent another class of host-directed agents; structure-activity relationship optimization yielded analogues with >11-fold improved anti-VEEV activity (EC50 = 7.2 µM) and complete elimination of progesterone receptor antagonism, thereby separating antiviral efficacy from abortifacient activity [80].

Antibody-Based Therapeutics: The Critical Role of Fc Effector Functions

Monoclonal antibodies (mAbs) targeting the VEEV E2 glycoprotein have demonstrated remarkable prophylactic and therapeutic efficacy in both murine and nonhuman primate (NHP) models, yet the mechanism of protection extends far beyond simple neutralization [60, 70, 71]. Comparative studies of the potently neutralizing human antibody hF5 with intact Fc function (hF5-WT) versus a variant containing L234A/L235A (LALA) mutations that abrogate Fcγ receptor and complement binding revealed that Fc effector functions are dispensable for protection when administered 24 hours before or 24 hours after infection. However, when treatment was delayed to 48 hours post-infection, hF5-LALA exhibited significantly reduced therapeutic efficacy compared to hF5-WT, demonstrating that engagement of immune effectors becomes critical during established infection [70]. In NHP models of aerosolized VEEV exposure, post-exposure administration of the chimeric antibody c1A3B-7 (containing mouse variable regions on a human IgG framework) at 24 hours post-challenge significantly reduced viremia, lymphopenia, and fever, with approximately 50% reduction in fever burden. Even when treatment was delayed to 48 hours post-exposure, c1A3B-7 still provided protection from severe disease [71]. Importantly, viral mutations were identified in one NHP after c1A3B-7 treatment, suggesting that cocktail-based antibody therapies or mAbs targeting epitopes with high fitness costs for escape mutations may be necessary for optimal therapeutic durability [71].

The development of single domain antibodies (sdAbs or nanobodies) derived from llama immunization has opened new avenues for therapeutic engineering. Bivalent sdAb constructs demonstrated neutralization of VEEV with 50% plaque reduction at protein concentrations of 1 ng/mL or lower, a two orders of magnitude improvement over monovalent formats, and some constructs cross-neutralized CHIKV, highlighting the potential for pan-alphavirus therapeutics [82]. Notably, the broadly cross-reactive E1-specific mAb 1A4B-6, despite only weakly neutralizing VEEV in vitro, protected mice prophylactically from lethal challenge by inhibiting virus-mediated cell fusion after pre-incubation at 37°C, suggesting that exposure of cryptic epitopes on E1 can be exploited for therapeutic benefit [50].

Receptor-Targeted and Decoy-Based Strategies

The identification of low-density lipoprotein receptor class A domain-containing 3 (LDLRAD3) as the primary entry receptor for VEEV has opened unprecedented opportunities for receptor-targeted interventions [5, 14, 18]. LDLRAD3 domain 1 (D1) is necessary and sufficient to support VEEV infection, and a soluble LDLRAD

Prevention and Control Measures for Venezuelan Equine Encephalitis Virus

The prevention and control of Venezuelan equine encephalitis virus (VEEV) represent a formidable challenge that demands an integrated, multi-pronged approach spanning veterinary medicine, public health, vector ecology, and molecular virology. As a zoonotic, vector-borne pathogen with proven epizootic potential and a history of weaponization, VEEV requires robust strategies targeting every node of its transmission cycle, from the enzootic maintenance hosts and mosquito vectors to susceptible equine populations and, ultimately, human communities. Effective control measures must be grounded in a deep understanding of the virus’s complex ecology, its rapid evolutionary capacity, and the specific vulnerabilities of its replication cycle that can be exploited for intervention. This section provides a comprehensive, evidence-based analysis of current and emerging strategies for the prevention and control of VEEV, drawing upon the latest research in vaccinology, antiviral development, vector surveillance, and outbreak management.

Vector Control and Environmental Management

The cornerstone of VEEV prevention, particularly for enzootic subtypes, is the strategic management of mosquito vector populations. The primary enzootic vectors belong to the Culex (Melanoconion) subgenus, with species such as Culex (Melanoconion) cedecei in Florida and Culex (Melanoconion) pedroi and Culex (Melanoconion) spissipes in Central and South America being well-documented transmitters [9, 15, 20]. Effective surveillance of these vectors is complicated by their cryptic resting behaviors and species-specific trapping preferences. A landmark study evaluating sampling strategies in Florida and Panama demonstrated that no single trapping method is universally effective for all species and physiological states. For example, the mosquito drift fence was most effective for collecting blood-engorged Cx. pedroi (57.6% of captures), while pop-up resting shelters were optimal for blood-engorged Cx. spissipes (42.3%) [15]. In Florida, the large-diameter aspirator was best for blood-engorged Cx. panocossa (41.9%), whereas CDC light traps with CO2 captured 84.5% of unfed Cx. cedecei [15]. These findings underscore that vector control programs must be tailored to local vector species and their behavioral ecology to achieve meaningful reductions in transmission risk.

Environmental modification plays an equally critical role. The establishment of Culex panocossa in Florida, coupled with Everglades restoration efforts that alter hydrology, may expand suitable habitats for VEEV vectors [9]. Climate change projections, including increased precipitation and temperature shifts, are modeled to expand the geographic range of VEEV in Costa Rica, with mean temperature of the coldest quarter (Bio11) and precipitation of the driest quarter (Bio17) being the strongest predictors of suitable habitat [67]. These environmental niche models can inform proactive vector control zoning. Livestock and horse owners should implement integrated mosquito management (IMM) practices, including removal of artificial containers, drainage of standing water, application of larvicides (e.g., Bacillus thuringiensis israelensis, methoprene) to breeding sites, and strategic use of adulticides during epizootic threats. The World Organisation for Animal Health (WOAH) recommends that such measures be intensified during recognized outbreak seasons, particularly in lowland areas below 100 meters above sea level, which has been identified as a significant risk factor for VEEV seropositivity in equids [37].

Vaccination Strategies: The First Line of Defense

Vaccination of equids remains the most effective and ethically imperative measure for preventing VEEV epizootics, as horses serve as the primary amplification hosts that bridge enzootic cycles to human populations. Several vaccine platforms have been developed, each with distinct advantages and limitations.

Live-Attenuated Vaccines: The TC-83 strain has served as the investigational live-attenuated vaccine for decades, derived from the epizootic IAB subtype. However, TC-83 is associated with significant drawbacks, including high reactogenicity (fever, ataxia, abortion in pregnant mares) and a non-response rate of approximately 20% in humans and variable seroconversion in equids [25, 35, 84, 85]. In murine models, TC-83 can cause persistent brain infection in immunocompromised animals lacking functional αβ T-cells, raising safety concerns for use in populations with undiagnosed immune deficiencies [69]. To address these issues, a novel DNA-launched vaccine candidate, V4020, was developed by rearranging the structural gene order (placing capsid downstream of glycoproteins) and incorporating stabilizing mutations in E2-120 [86]. In comparative murine studies, V4020 demonstrated significantly greater attenuation than TC-83 after intracranial inoculation, with lower clinical scores, reduced viral loads in the brain, and earlier viral clearance [84]. Critically, serial brain passage of V4020 resulted in no mortality and lower mutation rates in the nsP4 (RdRp) gene, whereas 13.3% of TC-83-inoculated mice met euthanasia criteria [84]. These data suggest that V4020 offers an improved safety profile while maintaining protective efficacy.

Replicon Particle and Self-Amplifying RNA Vaccines: The use of Venezuelan equine encephalitis virus replicon particles (VRPs) represents a highly immunogenic and safe platform. VRPs are single-cycle, propagation-defective particles that express heterologous antigens but cannot produce infectious progeny. A trivalent WEVEE VRP vaccine (encoding antigens from VEEV, EEEV, and WEEV) was shown to be immunogenic and protective in cynomolgus macaques, with vaccinated animals exhibiting significantly reduced fever hours and no mortality following aerosol WEEV challenge, compared to controls [61]. Furthermore, a non-select agent VRP system based on the attenuated VEEV strain 3526 can be packaged under biosafety level 2 (BSL-2) conditions, making this platform broadly accessible for global vaccine development [87]. Self-amplifying mRNA (SAM) vaccines formulated with cationic nanoemulsions have also demonstrated proof-of-concept: the LAV-CNE vaccine (launching a TC-83 genome) elicited immune responses equivalent to live virus and provided 100% protection against aerosol VEEV challenge in mice, while the irreversibly attenuated IAV-CNE (lacking capsid) offered significant protection without generating infectious virus [85].

Virus-Like Particle (VLP) and Subunit Vaccines: A trivalent VLP vaccine (WEVEE VLP) composed of VEEV, EEEV, and WEEV antigens was evaluated in a phase 1 randomized clinical trial in humans [72]. The vaccine was safe and well-tolerated, with the most common adverse events being mild injection-site pain and malaise. Neutralizing antibody responses were induced against all three vaccine components in the majority of participants (76% seroconverted to all three), with the highest geometric mean titers observed in the 30 μg + alum group (VEEV PRNT80 GMT = 111.5) [72]. This favorable safety and immunogenicity profile supports further clinical development. Additionally, a modified vaccinia Ankara (MVA)-based trivalent vaccine (MVA-WEV) encoding the polyproteins of all three equine encephalitis viruses in a single vector provided complete protection against homologous (VEEV Trinidad Donkey) and heterologous (VEEV INH-9813) aerosol challenge in mice, with neutralizing antibodies and interferon-gamma T-cell responses detected post-vaccination [65].

DNA Vaccines and Genetic Adjuvants: DNA vaccines offer logistical advantages in stability and production speed. Nanoplasmid vectors co-expressing innate immune agonists (type I interferon inducers) significantly enhanced antibody responses and protective efficacy against aerosol VEEV challenge in mice compared to conventional plasmid vectors [83]. Co-delivery of a DNA vaccine encoding IL-12 as a genetic adjuvant provided complete protection against aerosol VEEV challenge following simple intramuscular injection (without electroporation), achieving immunogenicity comparable to electroporation-delivered vaccines [88]. These approaches are particularly relevant for rapid deployment during outbreaks in resource-limited settings.

Antiviral Therapeutics: Direct-Acting and Host-Directed Strategies

No FDA-approved antiviral therapeutics currently exist for VEEV, but a robust pipeline of candidates targeting both viral and host factors has emerged from recent research.

Direct-Acting Antivirals Targeting Viral Enzymes: The VEEV nsP2 cysteine protease is essential for polyprotein processing and is a validated drug target. High-throughput screening and structure-based design have identified several promising inhibitor classes. Epoxysuccinyl prodrugs (E64d, CA074 methyl ester) and reversible oxindole inhibitors have demonstrated potent activity, with CA074me reducing viral titers by >5 logs in cell culture [6]. Hybrid inhibitors designed based on X-ray crystal structures of the nsP2 protease-inhibitor complexes showed improved potency, with the lead compound NCGC00488909-01 achieving an EC50 of 1.76 μM against VEEV-TrD [6]. Vinyl sulfone-based covalent inhibitors also exhibited promising activity, with compound 11 showing EC50 values of 2.4 μM (HeLa) and 1.6 μM (Vero E6) against VEEV TrD [77]. The benzamidine ML336 inhibits viral RNA synthesis by targeting the replicase complex, with an IC50 of 1.1 nM for RNA synthesis inhibition, and blocks both plus- and minus-strand RNA synthesis without affecting host transcription [54]. Resistance mutations to ML336 map to nsP2 (stalk domain) and nsP4 (RdRp), providing structural insights for next-generation inhibitor design [66]. Quinolinone compounds identified from a high-throughput screen also target nsP2, with resistance mutations mapping to Y102S/C in the helicase stalk domain; introducing the reciprocal K102Y mutation into chikungunya virus enhanced its sensitivity, confirming the mechanism [51].

The nsP1 capping enzyme is another attractive target. An ELISA-based high-throughput screen of 1,220 approved drugs identified 18 compounds inhibiting nsP1 guanylylation, with two chemical series showing specific inhibition of methyltransferase activity without affecting cellular methyltransferases [34]. The ribonucleoside analog EIDD-1931 (β-D-N4-hydroxycytidine, NHC) exhibits broad-spectrum activity against alphaviruses, including VEEV, and has a high genetic barrier to resistance. In a murine intranasal challenge model, oral administration of EIDD-1931 was 90-100% effective when initiated up to 24 hours post-infection, and partial protection was observed even with 48-hour delayed treatment, demonstrating its ability to penetrate the blood-brain barrier and suppress brain replication [63].

Host-Directed Therapies: The host-pathogen interface offers numerous vulnerabilities that can be exploited therapeutically. The NRF2 activator omaveloxolone (OMA), an FDA-approved drug, redirects host transcription from an interferon-centric, inflammatory response toward a cytoprotective antioxidant program while preserving core antiviral mechanisms [47]. In VEEV-infected human umbilical vein endothelial cells, OMA treatment upregulated 729 genes (including HMOX1, NQO1, GCLM, TXNRD1) associated with NRF2-dependent pathways, while repressing histone cluster genes and maintaining a compact interferon-centered antiviral backbone [47]. In a human blood-brain barrier organ-on-a-chip model, OMA treatment preserved barrier integrity and decreased both viral and inflammatory loads, suggesting its utility in mitigating neuroinvasion [49].

The Toll-like receptor 4 (TLR4) pathway represents another critical target. In C3H mice, TLR4-defective animals (C3H/HeJ) survived VEEV TC-83 infection, whereas TLR4-competent animals succumbed, with significantly reduced blood-brain barrier permeability and lower levels of MMP-9, MMP-2, ICAM-1, CCL2, and IFN-γ in the brains of TLR4-defective mice [19]. TLR4 antagonists could therefore reduce neurologic disease without directly inhibiting viral replication. Similarly, the AKT/GSK-3 pathway is essential for VEEV replication, and its inhibition by resveratrol, a natural phytochemical, reduced viral replication in Vero and U87MG cells through decreased phosphorylation of AKT/GSK-3 early in infection, complemented by direct binding to VEEV glycoproteins as predicted by molecular docking [76]. The multikinase inhibitor sorafenib, an FDA-approved cancer therapeutic, also inhibits VEEV replication (selectivity index >19) by dephosphorylating eIF4E and p70S6K, thereby suppressing viral translation [81].

Monoclonal Antibodies and Immunotherapeutics: Neutralizing monoclonal antibodies (mAbs) targeting the E2 glycoprotein have shown remarkable efficacy. The humanized mAb hF5, when administered 24 hours post-infection, provided high levels of protection in mice; however, when treatment was delayed to 48 hours, the loss-of-function Fc mutant (hF5-LALA) showed significantly reduced efficacy compared to wild-type hF5, demonstrating that Fc effector functions (complement binding, antibody-dependent cellular cytotoxicity) are essential for optimal therapeutic activity against VEEV [70]. In nonhuman primates, the chimeric mAb c1A3B-7, administered as a single intravenous dose 24-48 hours after aerosol VEEV exposure, significantly reduced viremia, fever, and lymphopenia [71]. Viral mutations were detected in one NHP after treatment, suggesting that a cocktail of mAbs targeting different epitopes may be necessary to prevent escape [71]. Single-domain antibodies (nanobodies) derived from llama immunization also show promise, with bivalent constructs achieving

References

[1] Rivera LF, Lezcano-Coba C, Galué J, Rodriguez X, Juarez Y, Souza WMd, et al.. Characteristics of Madariaga and Venezuelan Equine Encephalitis Virus Infections, Panama. Emerging Infectious Diseases. 2024. DOI: https://doi.org/10.3201/eid3014.240182

[2] Cain MD, Klein NR, Jiang X, Salimi H, Wu Q, Miller MJ, et al.. Post-exposure intranasal IFNα suppresses replication and neuroinvasion of Venezuelan Equine Encephalitis virus within olfactory sensory neurons. Journal of Neuroinflammation. 2024. DOI: https://doi.org/10.1186/s12974-023-02960-1

[3] León B, González G, Nicoli A, Rojas A, Pizio A, Ramĩrez-Carvajal L, et al.. Phylogenetic and Mutation Analysis of the Venezuelan Equine Encephalitis Virus Sequence Isolated in Costa Rica from a Mare with Encephalitis. Veterinary Sciences. 2022. DOI: https://doi.org/10.3390/vetsci9060258

[4] Xie Y, Cao J, Gan S, Xu L, Zhang D, Qian S, et al.. TRIM32 inhibits Venezuelan Equine Encephalitis Virus Infection by targeting a late step in viral entry. bioRxiv. 2024. DOI: https://doi.org/10.1101/2024.06.04.597282

[5] Kafai NM, Janova H, Cain MD, Alippe Y, Muraro S, Sariol A, et al.. Entry receptor LDLRAD3 is required for Venezuelan equine encephalitis virus peripheral infection and neurotropism leading to pathogenesis in mice. Cell Reports. 2023. DOI: https://doi.org/10.1016/j.celrep.2023.112946

[6] Hu X, Morazzani EM, Compton J, Harmon M, Soloveva V, Glass P, et al.. In Silico Screening of Inhibitors of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease. Viruses. 2023. DOI: https://doi.org/10.3390/v15071503

[7] Williams EP, Xue Y, Lee J, Fitzpatrick E, Kong Y, Reichard W, et al.. Deep spatial profiling of Venezuelan equine encephalitis virus reveals increased genetic diversity amidst neuroinflammation and cell death during brain infection. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.00827-23

[8] Panny L, Akrhymuk I, Bracci NR, Woodson CM, Flor R, Zhou W, et al.. Venezuelan equine encephalitis virus E1 protein interacts with PDIA6 and PDI inhibition reduces alphavirus production.. Antiviral Research. 2023. DOI: https://doi.org/10.1016/j.antiviral.2023.105560

[9] BURKETT-CADENA N, Fish D, Weaver S, Vittor A. Everglades virus: an underrecognized disease-causing subtype of Venezuelan equine encephalitis virus endemic to Florida, USA. Journal of medical entomology. 2023. DOI: https://doi.org/10.1093/jme/tjad070

[10] Hoffka G, Lountos G, Needle D, Wlodawer A, Waugh D, Tőzsér J, et al.. Self-inhibited State of Venezuelan Equine Encephalitis Virus (VEEV) nsP2 Cysteine Protease: A Crystallographic and Molecular Dynamics Analysis. Journal of Molecular Biology. 2023. DOI: https://doi.org/10.1016/j.jmb.2023.168012

[11] Cain MD, Klein NR, Jiang X, Klein R. Post-exposure intranasal IFNα suppresses replication and neuroinvasion of Venezuelan Equine Encephalitis virus within olfactory sensory neurons. bioRxiv. 2023. DOI: https://doi.org/10.1101/2023.06.30.547169

[12] Akhrymuk I, Lin S, Sun M, Patnaik A, Lehman C, Altamura L, et al.. Magnetic Nanotrap Particles Preserve the Stability of Venezuelan Equine Encephalitis Virus in Blood for Laboratory Detection. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2019.00509

[13] Guzmán C, Calderón A, Oviedo T, Mattar S, Castañeda J, Rodríguez V, et al.. Molecular and cellular evidence of natural Venezuelan equine encephalitis virus infection in frugivorous bats in Colombia. Veterinary World. 2020. DOI: https://doi.org/10.14202/vetworld.2020.495-501

[14] Basore K, Ma H, Kafai NM, Mackin SR, Kim AS, Nelson C, et al.. Structure of Venezuelan equine encephalitis virus in complex with the LDLRAD3 receptor. Nature. 2021. DOI: https://doi.org/10.1038/s41586-021-03963-9

[15] Sloyer KE, Santos M, Rivera E, Reeves LE, Carrera J, Vittor A, et al.. Evaluating sampling strategies for enzootic Venezuelan equine encephalitis virus vectors in Florida and Panama. PLoS Neglected Tropical Diseases. 2022. DOI: https://doi.org/10.1371/journal.pntd.0010329

[16] Behnia M, Baer A, Skidmore AM, Lehman C, Bracci NR, Kehn-Hall K, et al.. Inactivation of Venezuelan Equine Encephalitis Virus Genome Using Two Methods. Viruses. 2022. DOI: https://doi.org/10.3390/v14020272

[17] Silva FA, Ferreira MS, Araújo PA, Casseb SM, Silva SP, Neto JNN, et al.. Serological and Molecular Evidence of the Circulation of the Venezuelan Equine Encephalitis Virus Subtype IIIA in Humans, Wild Vertebrates and Mosquitos in the Brazilian Amazon. Viruses. 2022. DOI: https://doi.org/10.3390/v14112391

[18] Ma H, Kim AS, Kafai NM, Earnest JT, Shah AP, Case J, et al.. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2915-3

[19] Hollidge BS, Cohen CA, Frimpong JA, Badger C, Dye J, Schmaljohn C. Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection. Virulence. 2021. DOI: https://doi.org/10.1080/21505594.2020.1870834

[20] Guzmán-Terán C, Calderón-Rangel A, Rodríguez-Morales A, Mattar S. Venezuelan equine encephalitis virus: the problem is not over for tropical America. Annals of Clinical Microbiology and Antimicrobials. 2020. DOI: https://doi.org/10.1186/s12941-020-00360-4

[21] Bakovic A, Bhalla N, Alem F, Campbell C, Zhou W, Narayanan A. Inhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3. Viruses. 2021. DOI: https://doi.org/10.3390/v13081533

[22] Granda OO, Valle C, Shannon A, Decroly E, Canard B, Coutard B, et al.. Structure and Sequence Requirements for RNA Capping at the Venezuelan Equine Encephalitis Virus RNA 5′ End. Journal of Virology. 2021. DOI: https://doi.org/10.1128/JVI.00777-21

[23] Costa V, Tavares L, jo SDAú, Phelps A, Salguero F, Hunter L, et al.. Tumour Necrosis Factor-α, Chemokines, and Leukocyte Infiltrate Are Biomarkers for Pathology in the Brains of Venezuelan Equine Encephalitis (VEEV)-Infected Mice. Viruses. 2023. DOI: https://doi.org/10.3390/v15061307

[24] Carrera J, Araúz D, Rojas A, Cardozo F, Stittleburg V, Claro IM, et al.. Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga, and Eastern equine encephalitis viruses: application in human and mosquito public health surveillance in Panama. Journal of Clinical Microbiology. 2023. DOI: https://doi.org/10.1128/jcm.00152-23

[25] Sharma A, Knollmann-Ritschel B. Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development. Viruses. 2019. DOI: https://doi.org/10.3390/v11020164

[26] Ahmed A, Siman-Tov G, Keck F, Kortchak S, Bakovic A, Risner KH, et al.. Human cathelicidin peptide LL‐37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.02.002

[27] Luethy D. Eastern, Western, and Venezuelan Equine Encephalitis and West Nile Viruses: Clinical and Public Health Considerations.. The Veterinary clinics of North America. Equine practice. 2023. DOI: https://doi.org/10.1016/j.cveq.2022.11.007

[28] Bakovic A, Bhalla N, Kortchak S, Sun C, Zhou W, Ahmed A, et al.. Venezuelan Equine Encephalitis Virus nsP3 Phosphorylation Can Be Mediated by IKKβ Kinase Activity and Abrogation of Phosphorylation Inhibits Negative-Strand Synthesis. Viruses. 2020. DOI: https://doi.org/10.3390/v12091021

[29] Carey B, Akhrymuk I, Dahal B, Pinkham C, Bracci NR, Finstuen-Magro S, et al.. Protein Kinase C subtype δ interacts with Venezuelan equine encephalitis virus capsid protein and regulates viral RNA binding through modulation of capsid phosphorylation. PLoS Pathogens. 2020. DOI: https://doi.org/10.1371/journal.ppat.1008282

[30] Ahmed A, Bakovic A, Risner KH, Kortchak S, Torres MDT, Fuente-Nunez Cdl, et al.. Synthetic Host Defense Peptides Inhibit Venezuelan Equine Encephalitis Virus Replication and the Associated Inflammatory Response. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-77990-3

[31] Agback P, Shernyukov A, Dominguez F, Agback T, Frolova E. Novel NMR Assignment Strategy Reveals Structural Heterogeneity in Solution of the nsP3 HVD Domain of Venezuelan Equine Encephalitis Virus. Molecules. 2020. DOI: https://doi.org/10.3390/molecules25245824

[32] Bocan T, Stafford RG, Brown JL, Frimpong JA, Basuli F, Hollidge BS, et al.. Characterization of Brain Inflammation, Apoptosis, Hypoxia, Blood-Brain Barrier Integrity and Metabolism in Venezuelan Equine Encephalitis Virus (VEEV TC-83) Exposed Mice by In Vivo Positron Emission Tomography Imaging. Viruses. 2019. DOI: https://doi.org/10.3390/v11111052

[33] Meshram C, Phillips A, Lukash T, Shiliaev NG, Frolova E, Frolov I. Mutations in Hypervariable Domain of Venezuelan Equine Encephalitis Virus nsP3 Protein Differentially Affect Viral Replication. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01841-19

[34] Ferreira‐Ramos AS, Li C, Eydoux C, Contreras J, Morice C, Quérat G, et al.. Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno‐based assay. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.01.003

[35] Rusnak J, Glass P, Weaver S, Sabourin C, Glenn AM, Klimstra W, et al.. Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule. Viruses. 2019. DOI: https://doi.org/10.3390/v11090807

[36] Thomas DR, Lundberg L, Pinkham C, Shechter S, Debono AJ, Baell J, et al.. Identification of novel antivirals inhibiting recognition of Venezuelan equine encephalitis virus capsid protein by the Importin &agr;/&bgr;1 heterodimer through high‐throughput screening. Antiviral Research. 2018. DOI: https://doi.org/10.1016/j.antiviral.2018.01.007

[37] León B, Käsbohrer A, Hutter SE, Baldi M, Firth C, Romero-Zúñiga J, et al.. National Seroprevalence and Risk Factors for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis in Costa Rica.. Journal of Equine Veterinary Science. 2020. DOI: https://doi.org/10.1016/j.jevs.2020.103140

[38] Lundberg L, Carey B, Kehn-Hall K. Venezuelan Equine Encephalitis Virus Capsid, The Clever Caper. Viruses. 2017. DOI: https://doi.org/10.3390/v9100279

[39] Parvate A, Vago F, Hasan S, Lee J, Williams EP, Lanman J, et al.. A New Inactivation Method to Facilitate Cryo-EM of Enveloped, RNA Viruses Requiring High Containment: A Case Study using Venezuelan Equine Encephalitis Virus (VEEV).. Journal of Virological Methods. 2019. DOI: https://doi.org/10.1016/j.jviromet.2019.113792

[40] Kautz TF, Guerbois M, Khanipov K, Patterson EI, Langsjoen RM, Yun R, et al.. Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy. Virus Evolution. 2018. DOI: https://doi.org/10.1093/ve/vey004

[41] Carey B, Ammosova T, Pinkham C, Lin X, Zhou W, Liotta L, et al.. Protein Phosphatase 1α Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.02068-17

[42] Lundberg L, Fontenot J, Lin S, Pinkham C, Carey B, Campbell C, et al.. Venezuelan Equine Encephalitis Virus Capsid Implicated in Infection-Induced Cell Cycle Delay in vitro. Frontiers in Microbiology. 2018. DOI: https://doi.org/10.3389/fmicb.2018.03126

[43] Shechter S, Thomas DR, Lundberg L, Pinkham C, Lin S, Wagstaff K, et al.. Novel inhibitors targeting Venezuelan equine encephalitis virus capsid protein identified using In Silico Structure-Based-Drug-Design. Scientific Reports. 2017. DOI: https://doi.org/10.1038/s41598-017-17672-9

[44] Gupta P, Sharma A, Han J, Yang AX, Bhomia M, Knollmann-Ritschel B, et al.. Differential host gene responses from infection with neurovirulent and partially-neurovirulent strains of Venezuelan equine encephalitis virus. BMC Infectious Diseases. 2017. DOI: https://doi.org/10.1186/s12879-017-2355-3

[45] Guzmán C, Calderón A, Martinez C, Oviedo M, Mattar S. Eco-epidemiology of the Venezuelan equine encephalitis virus in bats of Córdoba and Sucre, Colombia. Acta Tropica. 2018. DOI: https://doi.org/10.1016/j.actatropica.2018.12.016

[46] Hu X, Compton J, Leary DH, Olson M, Lee MS, Cheung J, et al.. Kinetic, Mutational, and Structural Studies of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease. Biochemistry. 2016. DOI: https://doi.org/10.1021/acs.biochem.5b00992

[47] Rezapour M, Opoku LA, Trefry SV, Alili A, Konadu M, Dionisio MG, et al.. Transcriptomic profiling of human endothelial cells infected with venezuelan equine encephalitis virus reveals NRF2 driven host reprogramming mediated by omaveloxolone treatment. Frontiers in Genetics. 2025. DOI: https://doi.org/10.3389/fgene.2025.1722527

[48] Duven M, Friedrichs A, Tomlinson MG, Steffen I, Gerold G. Tetraspanins 10 and 15 support Venezuelan equine encephalitis virus replication in astrocytoma cells. Molecular Biology of the Cell. 2025. DOI: https://doi.org/10.1091/mbc.E24-12-0574

[49] Boghdeh NA, Risner KH, Barrera MD, Britt CM, Schaffer D, Alem F, et al.. Application of a Human Blood Brain Barrier Organ-on-a-Chip Model to Evaluate Small Molecule Effectiveness against Venezuelan Equine Encephalitis Virus. Viruses. 2022. DOI: https://doi.org/10.3390/v14122799

[50] Calvert AE, Bennett SL, Hunt A, Fong RH, Doranz B, Roehrig J, et al.. Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection. Virology. 2021. DOI: https://doi.org/10.1016/j.virol.2021.09.007

[51] Haese NN, May NA, Taft-Benz S, Moukha-Chafiq O, Madadi N, Zhang S, et al.. Identification of Quinolinones as Antivirals against Venezuelan Equine Encephalitis Virus. Antimicrobial Agents and Chemotherapy. 2021. DOI: https://doi.org/10.1128/AAC.00244-21

[52] Morazzani EM, Compton J, Leary DH, Berry AV, Hu X, Marugan J, et al.. Proteolytic cleavage of Host Proteins by the Group IV Viral Proteases of Venezuelan Equine Encephalitis Virus and Zika Virus. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.02.001

[53] Dahal B, Lin S, Carey B, Jacobs JL, Dinman J, Hoek MVv, et al.. EGR1 upregulation following Venezuelan equine encephalitis virus infection is regulated by ERK and PERK pathways contributing to cell death. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2019.10.016

[54] Skidmore AM, Adcock RS, Jonsson C, Golden JE, Chung D. Benzamidine ML336 inhibits plus and minus strand RNA synthesis of Venezuelan equine encephalitis virus without affecting host RNA production.. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.104674

[55] Keck F, Brooks-Faulconer T, Lark TJ, Ravishankar P, Bailey C, Salvador-Morales C, et al.. Altered mitochondrial dynamics as a consequence of Venezuelan Equine encephalitis virus infection. Virulence. 2017. DOI: https://doi.org/10.1080/21505594.2016.1276690

[56] Baer A, Lundberg L, Swales D, Waybright N, Pinkham C, Dinman J, et al.. Venezuelan Equine Encephalitis Virus Induces Apoptosis through the Unfolded Protein Response Activation of EGR1. Journal of Virology. 2016. DOI: https://doi.org/10.1128/JVI.02827-15

[57] Jo WK, Piche-Ovares M, Carranza L, Fischer C, Brünink S, Paul L, et al.. Venezuelan Equine Encephalitis Virus Infection in Nonhuman Primate, Guatemala, 2023. Emerging Infectious Diseases. 2025. DOI: https://doi.org/10.3201/eid3102.241484

[58] Piche-Ovares M, Mendoza MPG, Moreira-Soto A, Fischer C, Brünink S, Figueroa-Romero MD, et al.. Venezuelan Equine Encephalitis, Peruvian Amazon, 2020. Emerging Infectious Diseases. 2025. DOI: https://doi.org/10.3201/eid3105.241694

[59] Wang H, Liu S, Lv Y, Wei W. Codon usage bias of Venezuelan equine encephalitis virus and its host adaption. Virus Research. 2023. DOI: https://doi.org/10.1016/j.virusres.2023.199081

[60] Kafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Liu J, et al.. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. Journal of Experimental Medicine. 2022. DOI: https://doi.org/10.1084/jem.20212532

[61] Burke C, Erwin-Cohen R, Goodson AI, Wilhelmsen C, Edmundson JA, White CE, et al.. Efficacy of Western, Eastern, and Venezuelan Equine Encephalitis (WEVEE) Virus-Replicon Particle (VRP) Vaccine against WEEV in a Non-Human Primate Animal Model. Viruses. 2022. DOI: https://doi.org/10.3390/v14071502

[62] Ma H, Albe JR, Gilliland T, McMillen CM, Gardner CL, Boyles DA, et al.. Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus. bioRxiv. 2021. DOI: https://doi.org/10.1371/journal.ppat.1009946

[63] Painter G, Bowen R, Bluemling GR, Debergh J, Edpuganti V, Gruddanti PR, et al.. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.104597

[64] Burke C, Gardner CL, Goodson AI, Piper A, Erwin-Cohen R, White CE, et al.. Defining the Cynomolgus Macaque (Macaca fascicularis) Animal Model for Aerosolized Venezuelan Equine Encephalitis: Importance of Challenge Dose and Viral Subtype. Viruses. 2023. DOI: https://doi.org/10.3390/v15122351

[65] Henning LN, Endt K, Steigerwald R, Anderson M, Volkmann A. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge. Frontiers in Immunology. 2021. DOI: https://doi.org/10.3389/fimmu.2020.598847

[66] Lee J, Parvathareddy J, Yang D, Bansal S, O’Connell K, Golden JE, et al.. Emergence and Magnitude of ML336 Resistance in Venezuelan Equine Encephalitis Virus Depend on the Microenvironment. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.00317-20

[67] León B, Jiménez-Sánchez C, Retamosa-Izaguirre M. An Environmental Niche Model to Estimate the Potential Presence of Venezuelan Equine Encephalitis Virus in Costa Rica. International Journal of Environmental Research and Public Health. 2020. DOI: https://doi.org/10.3390/ijerph18010227

[68] León B, Jiménez C, González R, Ramĩrez-Carvajal L. First Complete Coding Sequence of a Venezuelan Equine Encephalitis Virus Strain Isolated from an Equine Encephalitis Case in Costa Rica. Microbiology Resource Announcements. 2019. DOI: https://doi.org/10.1128/MRA.00672-19

[69] Taylor KG, Kolokoltsova OA, Ronca S, Estes M, Paessler S. Live, Attenuated Venezuelan Equine Encephalitis Virus Vaccine (TC83) Causes Persistent Brain Infection in Mice with Non-functional αβ T-Cells. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.00081

[70] Schwedler JL, Stefan M, Thatcher CE, Mcilroy P, Sinha A, Phillips AM, et al.. Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function. mAbs. 2024. DOI: https://doi.org/10.1080/19420862.2023.2297451

[71] Crystal W, BurkeID, Froude JW, Rossi FD, Charles E, WhiteID, et al.. Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure. PLoS Pathogens. 2019. DOI: https://doi.org/10.1371/journal.ppat.1008157

[72] Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, et al.. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a randomized clinical trial. Lancet. Infectious Diseases (Print). 2022. DOI: https://doi.org/10.1016/s1473-3099(22)00052-4

[73] Schultz EM, Jones TJ, Barr K. Antibodies for Venezuelan Equine Encephalitis Virus Protect Embryoid Bodies from Chikungunya Virus. Viruses. 2019. DOI: https://doi.org/10.3390/v12030262

[74] Patterson EI, Warmbrod KL, Bouyer D, Forrester N. Evaluation of the inactivation of Venezuelan equine encephalitis virus by several common methods. Journal of Virological Methods. 2018. DOI: https://doi.org/10.1016/j.jviromet.2018.01.009

[75] Yu G, Wiley M, Kugelman JR, Ladner J, Beitzel B, Eccleston LT, et al.. Complete Coding Sequences of Eastern Equine Encephalitis Virus and Venezuelan Equine Encephalitis Virus Strains Isolated from Human Cases. Genome Announcements. 2015. DOI: https://doi.org/10.1128/genomeA.00243-15

[76] Lehman C, Kehn-Hall K, Aggarwal M, Bracci NR, Pan H, Panny L, et al.. Resveratrol Inhibits Venezuelan Equine Encephalitis Virus Infection by Interfering with the AKT/GSK Pathway. Plants. 2021. DOI: https://doi.org/10.3390/plants10020346

[77] Zhang H, Harmon M, Radoshitzky S, Soloveva V, Kane CD, Duplantier A, et al.. Vinyl Sulfone-Based Inhibitors of Nonstructural Protein 2 Block the Replication of Venezuelan Equine Encephalitis Virus.. ACS Medicinal Chemistry Letters. 2020. DOI: https://doi.org/10.1021/acsmedchemlett.0c00215

[78] Yao Z, Zanini F, Kumar S, Karim M, Saul S, Bhalla N, et al.. The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection. bioRxiv. 2020. DOI: https://doi.org/10.1371/journal.pntd.0009306

[79] Risner KH, Ahmed A, Bakovic A, Kortchak S, Bhalla N, Narayanan A. Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection. Viruses. 2019. DOI: https://doi.org/10.3390/v11121151

[80] Debono AJ, Thomas DR, Lundberg L, Pinkham C, Cao Y, Graham J, et al.. Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-38671-y

[81] Lundberg L, Brahms A, Hooper I, Carey B, Lin S, Dahal B, et al.. Repurposed FDA‐Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses. Antiviral Research. 2018. DOI: https://doi.org/10.1016/j.antiviral.2018.07.005

[82] Liu JL, Zabetakis D, Gardner CL, Burke C, Glass P, Webb EM, et al.. Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis. Scientific Reports. 2022. DOI: https://doi.org/10.1038/s41598-021-04434-x

[83] Suschak J, Dupuy L, Shoemaker CJ, Six CM, Kwilas S, Spik K, et al.. Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus. Molecular Therapy: Methods & Clinical Development. 2020. DOI: https://doi.org/10.1016/j.omtm.2020.04.009

[84] Johnson DM, Sokoloski K, Jokinen JD, Pfeffer TL, Chu Y, Adcock RS, et al.. Advanced Safety and Genetic Stability in Mice of a Novel DNA-Launched Venezuelan Equine Encephalitis Virus Vaccine with Rearranged Structural Genes. Vaccines. 2020. DOI: https://doi.org/10.3390/vaccines8010114

[85] Samsa MM, Dupuy L, Beard C, Six CM, Schmaljohn C, Mason P, et al.. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.. Molecular Therapy. 2019. DOI: https://doi.org/10.1016/j.ymthe.2018.12.013

[86] Tretyakova I, Tibbens A, Jokinen JD, Johnson DM, Lukashevich I, Pushko P. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.. Vaccine. 2019. DOI: https://doi.org/10.1016/j.vaccine.2019.04.072

[87] Agnihothram S, Menachery VD, Yount B, Lindesmith L, Scobey TD, Whitmore A, et al.. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.00027-18

[88] Suschak J, Bagley K, Six CM, Shoemaker CJ, Kwilas S, Spik K, et al.. The genetic adjuvant IL‐12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice. Antiviral Research. 2018. DOI: https://doi.org/10.1016/j.antiviral.2018.09.014